| 1 | AbbVie | Humira | Adalimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 12,543 | 14,012 | 12,543 | 14,012 | 1,469 | 12% |
| 2 | AbbVie | Imbruvica | Ibrutinib | Chronic lymphocytic leukemia | USD | 0 | 754 | 0 | 754 | 754 | New Launch |
| 3 | AbbVie | Viekira Pak | Ombitasvir/Paritaprevir/Ritonavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 48 | 1,639 | 48 | 1,639 | 1,591 | 3315% |
| 4 | AbbVie | Creon | Pancrelipase | Rare Disease | USD | 516 | 632 | 516 | 632 | 116 | 22% |
| 5 | AbbVie | Synagis | Palivizumab | Respiratory Disorders | USD | 835 | 740 | 835 | 740 | -95 | -11% |
| 6 | AbbVie | Lupron | Leuprolide acetate | Oncology | USD | 778 | 826 | 778 | 826 | 48 | 6% |
| 7 | AbbVie | Synthroid | Levothyroxine Sodium | Hormonal Disorders | USD | 709 | 755 | 709 | 755 | 46 | 6% |
| 8 | AbbVie | Kaletra | Lopinavir/Ritonavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 870 | 700 | 870 | 700 | -170 | -20% |
| 9 | AbbVie | Androgel | Testosterone | Hormonal Disorders | USD | 934 | 694 | 934 | 694 | -240 | -26% |
| 10 | AbbVie | Sevoflurane | Sevoflurane | Others | USD | 550 | 474 | 550 | 474 | -76 | -14% |
| 11 | AbbVie | Duodopa | Carbidopa/Levodopa | Neuroscience and Mental Health | USD | 220 | 231 | 220 | 231 | 11 | 5% |
| 12 | AbbVie | Total: Other Mature Products | | | USD | 1,629 | 1,223 | 1,629 | 1,223 | -406 | -25% |
| 13 | AbbVie | Dyslipidemia products | | Cardiovascular | USD | 328 | 179 | 328 | 179 | -149 | -45% |
| 14 | AbbVie | Total Pharmaceuticals | | | USD | 19,960 | 22,859 | 19,960 | 22,859 | 2,899 | 15% |
| 15 | Alexion Pharmaceuticals | Soliris | Eculizumab | Blood Related Disorders | USD | 2,234 | 2,590 | 2,234 | 2,590 | 356 | 16% |
| 16 | Alexion Pharmaceuticals | Strensiq | Asfotase Alfa | Bone Health | USD | 0 | 12 | 0 | 12 | 12 | New Launch |
| 17 | Alexion Pharmaceuticals | Kanuma | Sebelipase Alfa | Lysosomal acid lipase deficiency | USD | 0 | 0 | 0 | 0 | 0 | New Launch |
| 18 | Alexion Pharmaceuticals | Total Product Sales | | | USD | 2,234 | 2,603 | 2,234 | 2,603 | 369 | 17% |
| 19 | Amgen | Enbrel | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | 4,688 | 5,364 | 4,688 | 5,364 | 676 | 14% |
| 20 | Amgen | Neulasta | Pegfilgrastim | Blood Related Disorders | USD | 4,596 | 4,715 | 4,596 | 4,715 | 119 | 3% |
| 21 | Amgen | Aranesp | Darbepoetin Alfa | Blood Related Disorders | USD | 1,930 | 1,951 | 1,930 | 1,951 | 21 | 1% |
| 22 | Amgen | Epogen | Epoetin Alfa | Blood Related Disorders | USD | 2,031 | 1,856 | 2,031 | 1,856 | -175 | -9% |
| 23 | Amgen | Sensipar /Mimpara | Cinacalcet | Hormonal Disorders | USD | 1,158 | 1,415 | 1,158 | 1,415 | 257 | 22% |
| 24 | Amgen | Xgeva | Denosumab | Oncology | USD | 1,221 | 1,405 | 1,221 | 1,405 | 184 | 15% |
| 25 | Amgen | Prolia | Denosumab | Bone Health | USD | 1,030 | 1,312 | 1,030 | 1,312 | 282 | 27% |
| 26 | Amgen | Neupogen | Filgrastim | Blood Related Disorders | USD | 1,159 | 1,049 | 1,159 | 1,049 | -110 | -9% |
| 27 | Amgen | Vectibix | Panitumumab | Oncology | USD | 505 | 549 | 505 | 549 | 44 | 9% |
| 28 | Amgen | Nplate | Romiplostim | Immunology (Organ Transplant, Arthritis etc.) | USD | 469 | 525 | 469 | 525 | 56 | 12% |
| 29 | Amgen | Kyprolis | Carfilzomib | Oncology | USD | 331 | 512 | 331 | 512 | 181 | 55% |
| 30 | Amgen | Other | | | USD | 209 | 291 | 209 | 291 | 82 | 39% |
| 31 | Amgen | Total Product sales | | | USD | 19,327 | 20,944 | 19,327 | 20,944 | 1,617 | 8% |
| 32 | Amgen | Other revenues | | | USD | 736 | 718 | 736 | 718 | -18 | -2% |
| 33 | Amgen | Total Revenues | | | USD | 20,063 | 21,662 | 20,063 | 21,662 | 1,599 | 8% |
| 34 | Astellas Pharma | Prograf | Tacrolimus | Immunology (Organ Transplant, Arthritis etc.) | YEN | 181054 | 194712 | 1,593 | 1,713 | 120 | 8% |
| 35 | Astellas Pharma | Xtandi | Enzalutamide | Oncology | YEN | 54,594 | 137,189 | 480 | 1,207 | 727 | 151% |
| 36 | Astellas Pharma | Vesicare | Solifenacin Succinate | Overactive Bladder | YEN | 133,845 | 135,241 | 1,178 | 1,190 | 12 | 1% |
| 37 | Astellas Pharma | Other | | | YEN | 770415 | 780,118 | 6,780 | 6,865 | 85 | 1% |
| 38 | Astellas Pharma | Total | | | YEN | 1139909 | 1247259 | 10,031 | 10,976 | 945 | 9% |
| 39 | AstraZeneca | Symbicort | Budesonide and Formoterol | Respiratory Disorders | USD | 3,801 | 3,394 | 3,801 | 3,394 | -407 | -11% |
| 40 | AstraZeneca | Pulmicort | Budesonide | Respiratory Disorders | USD | 946 | 1,014 | 946 | 1,014 | 68 | 7% |
| 41 | AstraZeneca | Tudorza/Eklira | Aclidinium Bromide | Respiratory Disorders | USD | 0 | 190 | 0 | 190 | 190 | New Launch |
| 42 | AstraZeneca | Daliresp | Roflumilast | Respiratory Disorders | USD | 0 | 104 | 0 | 104 | 104 | New Launch |
| 43 | AstraZeneca | Duaklir | Aclidinium Bromide/Formoterol Fumarate | Respiratory Disorders | USD | 0 | 27 | 0 | 27 | 27 | New Launch |
| 44 | AstraZeneca | Other Products | | | USD | 316 | 258 | 316 | 258 | -58 | -18% |
| 45 | AstraZeneca | Total: Respiratory, Inflammation and Autoimmunity | | | USD | 5,063 | 4,987 | 5,063 | 4,987 | -76 | -2% |
| 46 | AstraZeneca | Brilinta/Brilique | Ticagrelor | Cardiovascular | USD | 476 | 619 | 476 | 619 | 143 | 30% |
| 47 | AstraZeneca | Onglyza/Kombiglyze XR/Komboglyze | Saxagliptin/Saxagliptin+Metoprolol Hydrochloride | Diabetes | USD | 820 | 786 | 820 | 786 | -34 | -4% |
| 48 | AstraZeneca | Bydureon | Exenatide | Diabetes | USD | 440 | 580 | 440 | 580 | 140 | 32% |
| 49 | AstraZeneca | Farxiga/Forxiga | Dapagliflozin | Diabetes | USD | 0 | 492 | 0 | 492 | 492 | New Launch |
| 50 | AstraZeneca | Byetta | Exenatide | Diabetes | USD | 327 | 316 | 327 | 316 | -11 | -3% |
| 51 | AstraZeneca | Crestor | Rosuvastatin Calcium | Cardiovascular | USD | 5,512 | 5,017 | 5,512 | 5,017 | -495 | -9% |
| 52 | AstraZeneca | Seloken /Toprol-XL | Metoprolol Hydrochloride | Antihypertensives | USD | 758 | 710 | 758 | 710 | -48 | -6% |
| 53 | AstraZeneca | Atacand | Candesartan | Antihypertensives | USD | 501 | 358 | 501 | 358 | -143 | -29% |
| 54 | AstraZeneca | Plendil | Felodipine | Antihypertensives | USD | 249 | 0 | 249 | 0 | -249 | -100% |
| 55 | AstraZeneca | Tenormin | Atenolol | Antihypertensives | USD | 161 | 0 | 161 | 0 | -161 | -100% |
| 56 | AstraZeneca | Other Products | | | USD | 558 | 611 | 558 | 611 | 53 | 9% |
| 57 | AstraZeneca | Total: Cardiovascular and Metabolic Diseases | | | USD | 9,802 | 9,489 | 9,802 | 9,489 | -313 | -3% |
| 58 | AstraZeneca | Iressa | Gefitinib | Oncology | USD | 623 | 543 | 623 | 543 | -80 | -13% |
| 59 | AstraZeneca | Lynparza | Olaparib | Oncology | USD | 0 | 94 | 0 | 94 | 94 | New Launch |
| 60 | AstraZeneca | Tagrisso | Osimertinib | Oncology | USD | 0 | 19 | 0 | 19 | 19 | New Launch |
| 61 | AstraZeneca | Zoladex | Goserelin Acetate | Oncology | USD | 924 | 816 | 924 | 816 | -108 | -12% |
| 62 | AstraZeneca | Faslodex | Fulvestrant | Oncology | USD | 720 | 704 | 720 | 704 | -16 | -2% |
| 63 | AstraZeneca | Casodex | Bicalutamide | Oncology | USD | 320 | 267 | 320 | 267 | -53 | -17% |
| 64 | AstraZeneca | Arimidex | Anastrozole | Oncology | USD | 298 | 250 | 298 | 250 | -48 | -16% |
| 65 | AstraZeneca | Other Products | | | USD | 142 | 132 | 142 | 132 | -10 | -7% |
| 66 | AstraZeneca | Total: Oncology | | | USD | 3,027 | 2,825 | 3,027 | 2,825 | -202 | -7% |
| 67 | AstraZeneca | Nexium | Esomeprazole Magnesium | Gastrointestinal Disorders | USD | 3,655 | 2,496 | 3,655 | 2,496 | -1,159 | -32% |
| 68 | AstraZeneca | Seroquel XR | Quetiapine Fumarate | Neuroscience and Mental Health | USD | 1,224 | 1,025 | 1,224 | 1,025 | -199 | -16% |
| 69 | AstraZeneca | Seroquel IR | Quetiapine Fumarate | Neuroscience and Mental Health | USD | 178 | 0 | 178 | 0 | -178 | -100% |
| 70 | AstraZeneca | Synagis | Palivizumab | Respiratory Disorders | USD | 900 | 662 | 900 | 662 | -238 | -26% |
| 71 | AstraZeneca | Losec/Prilosec | Omeprazole | Gastrointestinal Disorders | USD | 422 | 340 | 422 | 340 | -82 | -19% |
| 72 | AstraZeneca | FluMist/Fluenz | Influenza Vaccine Live, Intranasal | Infectious Diseases (HIV, Hepatitis etc.) | USD | 295 | 288 | 295 | 288 | -7 | -2% |
| 73 | AstraZeneca | Movantik/Moventig | Naloxegol | Gastrointestinal Disorders | USD | 0 | 29 | 0 | 29 | 29 | New Launch |
| 74 | AstraZeneca | Merrem/Meronem | Meropenem | Neuroscience and Mental Health | USD | 253 | 0 | 253 | 0 | -253 | -100% |
| 75 | AstraZeneca | Local Anaesthetics | | | USD | 488 | 0 | 488 | 0 | -488 | -100% |
| 76 | AstraZeneca | Vimovo | Naproxen + Esomeprazole Magnesium | Bone Health | USD | 96 | 0 | 96 | 0 | -96 | -100% |
| 77 | AstraZeneca | Other Products (Infection, Neuroscience, Gastrointestinal) | | | USD | 692 | 1,500 | 692 | 1,500 | 808 | 117% |
| 78 | AstraZeneca | Total: Infection, Neuroscience, Gastrointestinal | | | USD | 8,203 | 6,340 | 8,203 | 6,340 | -1,863 | -23% |
| 79 | AstraZeneca | Total Pharmaceuticals | | | USD | 26,095 | 23,641 | 26,095 | 23,641 | -2,454 | -9% |
| 80 | Bayer | Xarelto | Rivaroxaban | Anticoagulants | EURO | 1,679 | 2,252 | 1,847 | 2,477 | 630 | 34% |
| 81 | Bayer | Eylea | Aflibercept | Diabetes | EURO | 759 | 1,228 | 835 | 1,351 | 516 | 62% |
| 82 | Bayer | Kogenate | Antihemophilic Factor (Recombinant) | Rare Disease | EURO | 1,109 | 1,155 | 1,220 | 1,271 | 51 | 4% |
| 83 | Bayer | Mirena Product Family | Levonorgestrel | Sexual Health | EURO | 819 | 968 | 901 | 1,065 | 164 | 18% |
| 84 | Bayer | Nexavar | Sorafenib | Oncology | EURO | 773 | 892 | 850 | 981 | 131 | 15% |
| 85 | Bayer | Betaferon/Betaseron | Interferon Beta-1b | Neuroscience and Mental Health | EURO | 823 | 824 | 901 | 906 | 5 | 1% |
| 86 | Bayer | YAZ/Yasim/Yasminelle | Drospirenone and Ethinyl Estradiol | Sexual Health | EURO | 768 | 706 | 845 | 777 | -68 | -8% |
| 87 | Bayer | Adalat | Nifedipine | Antihypertensives | EURO | 588 | 633 | 647 | 696 | 49 | 8% |
| 88 | Bayer | Aspirin Cardio | Acetylsalicylic Acid | Cardiovascular | EURO | 486 | 524 | 535 | 576 | 41 | 8% |
| 89 | Bayer | Glucobay | Acarbose | Diabetes | EURO | 443 | 523 | 487 | 575 | 88 | 18% |
| 90 | Bayer | Avalox/Avelox | Moxifloxacin Hydrochloride | Anti-bacterial | EURO | 381 | 379 | 419 | 417 | -2 | 0% |
| 91 | Bayer | Stivarga | Regorafenib | Oncology | EURO | 224 | 313 | 246 | 344 | 98 | 40% |
| 92 | Bayer | Xofigo | Radium Ra 223 dichloride | Oncology | EURO | 157 | 257 | 173 | 283 | 110 | 64% |
| 93 | Bayer | Levitra | Vardenafil Hydrochloride | Sexual Health | EURO | 245 | 226 | 270 | 249 | -21 | -8% |
| 94 | Bayer | Cipro/CiproBay | Ciprofloxacin | Anti-bacterial | EURO | 191 | 182 | 210 | 200 | -10 | -5% |
| 95 | Bayer | Pharmaceuticals | | | EURO | 9,445 | 11,062 | 10,390 | 12,168 | 1,778 | 17% |
| 96 | Bayer | Other Products | | | EURO | 2,607 | 2,683 | 2,868 | 2,951 | 83 | 3% |
| 97 | Bayer | Total Pharmaceuticals | | | EURO | 12,052 | 13,745 | 13,257 | 15,120 | 1,863 | 14% |
| 98 | Bayer | Consumer Health | | | EURO | 7,023 | 9,129 | 7,725 | 10,042 | 2,317 | 30% |
| 99 | Bayer | Total Healthcare | | | EURO | 19,075 | 22,874 | 20,983 | 25,161 | 4,178 | 20% |
| 100 | Bayer | Crop Science | | | EURO | 9,494 | 10,367 | 10,443 | 11,404 | 961 | 9% |
| 101 | Bayer | Covestro (Material Science) | | | EURO | 11,651 | 11,982 | 12,816 | 13,180 | 364 | 3% |
| 102 | Bayer | Other Revenues | | | EURO | 1,119 | 1,101 | 1,231 | 1,211 | -20 | -2% |
| 103 | Bayer | Group (incl. reconciliation) | | | EURO | 41,339 | 46,324 | 45,473 | 50,956 | 5,483 | 12% |
| 104 | Biogen | Tecfidera | Dimethyl Fumarate | Neuroscience and Mental Health | USD | 3,638 | 2,909 | 2,909 | 3,638 | 729 | 25% |
| 105 | Biogen | Avonex | Interferon beta-1a | Neuroscience and Mental Health | USD | 3,013 | 2,630 | 3,013 | 2,630 | -383 | -13% |
| 106 | Biogen | Plegridy | Peginterferon beta-1a | Neuroscience and Mental Health | USD | 45 | 339 | 45 | 339 | 294 | 653% |
| 107 | Biogen | Tysabri | Natalizumab | Neuroscience and Mental Health | USD | 1,960 | 1,886 | 1,960 | 1,886 | -74 | -4% |
| 108 | Biogen | Fampyra | Fampridine | Neuroscience and Mental Health | USD | 80 | 90 | 80 | 90 | 10 | 13% |
| 109 | Biogen | Total Multiple Sclerosis | | | USD | 8,007 | 8,583 | 8,007 | 8,583 | 576 | 7% |
| 110 | Biogen | Eloctate | Antihemophilic Factor (Recombinant), Fc Fusion Protein | Blood Related Disorders | USD | 58 | 320 | 58 | 320 | 262 | 452% |
| 111 | Biogen | Alprolix | Coagulation Factor IX (Recombinant), Fc Fusion Protein | Blood Related Disorders | USD | 76 | 235 | 76 | 235 | 159 | 209% |
| 112 | Biogen | Total Hemophilia | | | USD | 134 | 555 | 134 | 555 | 420 | 314% |
| 113 | Biogen | Fumaderm | Fumapharm AG | Anti-fungal | USD | 63 | 51 | 63 | 51 | -12 | -19% |
| 114 | Biogen | Other product revenues | | | USD | 63 | 51 | 63 | 51 | -12 | -19% |
| 115 | Biogen | Total product revenues | | | USD | 8,203 | 9,189 | 8,203 | 9,189 | 986 | 12% |
| 116 | Biogen | Unconsolidated joint business revenues | | | USD | 1,195 | 1,339 | 1,195 | 1,339 | 144 | 12% |
| 117 | Biogen | Other revenues | | | USD | 305 | 236 | 305 | 236 | -69 | -23% |
| 118 | Biogen | Total revenues | | | USD | 9,703 | 10,764 | 9,703 | 10,764 | 1,061 | 11% |
| 119 | Bristol-Myers Squibb | Baraclude | Entecavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,441 | 1,312 | 1,441 | 1,312 | -129 | -9% |
| 120 | Bristol-Myers Squibb | Hepatits C Franchise | Daclatasvir and Asunaprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 256 | 1,603 | 256 | 1,603 | 1,347 | 526% |
| 121 | Bristol-Myers Squibb | Reyataz | Atazanavir Sulphate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,362 | 1,139 | 1,362 | 1,139 | -223 | -16% |
| 122 | Bristol-Myers Squibb | Sustiva | Efavirenz | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,444 | 1,252 | 1,444 | 1,252 | -192 | -13% |
| 123 | Bristol-Myers Squibb | Total: Virology | | | USD | 4,503 | 5,306 | 4,503 | 5,306 | 803 | 18% |
| 124 | Bristol-Myers Squibb | Empliciti | Elotuzumab | Oncology | USD | 0 | 3 | 0 | 3 | 3 | New Launch |
| 125 | Bristol-Myers Squibb | Erbitux | Cetuximab | Oncology | USD | 723 | 501 | 723 | 501 | -222 | -31% |
| 126 | Bristol-Myers Squibb | Opdivo | Nivolumab | Oncology | USD | 6 | 942 | 6 | 942 | 936 | 15600% |
| 127 | Bristol-Myers Squibb | Sprycel | Dasatinib | Oncology | USD | 1,493 | 1,620 | 1,493 | 1,620 | 127 | 9% |
| 128 | Bristol-Myers Squibb | Yervoy | Ipilimumab | Oncology | USD | 1,308 | 1,126 | 1,308 | 1,126 | -182 | -14% |
| 129 | Bristol-Myers Squibb | Total: Oncology | | | USD | 3,530 | 4,192 | 3,530 | 4,192 | 662 | 19% |
| 130 | Bristol-Myers Squibb | Abilify | Aripiprazole | Neuroscience and Mental Health | USD | 2,020 | 746 | 2,020 | 746 | -1,274 | -63% |
| 131 | Bristol-Myers Squibb | Total: Neuroscience | | | USD | 2,020 | 746 | 2,020 | 746 | -1,274 | -63% |
| 132 | Bristol-Myers Squibb | Orencia | Abatacept | Immunology (Organ Transplant, Arthritis etc.) | USD | 1,652 | 1,885 | 1,652 | 1,885 | 233 | 14% |
| 133 | Bristol-Myers Squibb | Total: Immunoscience | | | USD | 1,652 | 1,885 | 1,652 | 1,885 | 233 | 14% |
| 134 | Bristol-Myers Squibb | Eliquis | Apixaban | Anticoagulants | USD | 774 | 1,860 | 774 | 1,860 | 1,086 | 140% |
| 135 | Bristol-Myers Squibb | Total: Cardiovascular | | | USD | 774 | 1,860 | 774 | 1,860 | 1,086 | 140% |
| 136 | Bristol-Myers Squibb | Diabetes Alliance(divested to Astra Zeneca in Feb 2014) | | | USD | 295 | 0 | 295 | 0 | -295 | -100% |
| 137 | Bristol-Myers Squibb | Total: Other Mature Products | | | USD | 3,400 | 2,571 | 3,400 | 2,571 | -829 | -24% |
| 138 | Bristol-Myers Squibb | Total Excluding Diabetes Alliance | | | USD | 15,584 | 16,364 | 15,584 | 16,364 | 780 | 5% |
| 139 | Bristol-Myers Squibb | Total Pharmaceuticals | | | USD | 15,879 | 16,560 | 15,879 | 16,560 | 681 | 4% |
| 140 | Celgene Corpoartion | Revlimid | Lenalidomide | Blood Related Disorders | USD | 4,980 | 5,801 | 4,980 | 5,801 | 821 | 16% |
| 141 | Celgene Corpoartion | Abraxane | Paclitaxel protein-bound | Oncology | USD | 848 | 968 | 848 | 968 | 120 | 14% |
| 142 | Celgene Corpoartion | Pomalyst /Imnovid | Pomalidomide | Oncology | USD | 680 | 983 | 680 | 983 | 303 | 45% |
| 143 | Celgene Corpoartion | Otezla | Apremilast | Skin Disorder | USD | 70 | 472 | 70 | 472 | 402 | 574% |
| 144 | Celgene Corpoartion | Vidaza | Azacitidine | Oncology | USD | 612 | 591 | 612 | 591 | -21 | -3% |
| 145 | Celgene Corpoartion | Azacitidine for injection | Azacitidine | | USD | 78 | 84 | 78 | 84 | 6 | 8% |
| 146 | Celgene Corpoartion | Thalomid | Thalidomide | Skin Disorder | USD | 221 | 185 | 221 | 185 | -36 | -16% |
| 147 | Celgene Corpoartion | Istodax | Romidepsin | Oncology | USD | 66 | 69 | 66 | 69 | 3 | 5% |
| 148 | Celgene Corpoartion | Other | | | USD | 9 | 8 | 9 | 8 | -1 | -11% |
| 149 | Celgene Corpoartion | Total net product sales | | | USD | 7,564 | 9,161 | 7,564 | 9,161 | 1,597 | 21% |
| 150 | Celgene Corpoartion | Other revenue | | | USD | 107 | 95 | 107 | 95 | -12 | -11% |
| 151 | Celgene Corpoartion | Total Revenues | | | USD | 7,670 | 9,256 | 7,670 | 9,256 | 1,586 | 21% |
| 152 | Chugai Pharmaceuticals | Oncology | | | YEN | 188,900 | 215,700 | 1,662 | 1,898 | 236 | 14% |
| 153 | Chugai Pharmaceuticals | Bone and Joint Diseases | | | YEN | 69,600 | 79,400 | 612 | 699 | 87 | 14% |
| 154 | Chugai Pharmaceuticals | Renal Diseases | | | YEN | 44,700 | 45,400 | 393 | 400 | 7 | 2% |
| 155 | Chugai Pharmaceuticals | Transplant, Immunoloty and Infectious Diseases | | | YEN | 20,800 | 15,900 | 183 | 140 | -43 | -23% |
| 156 | Chugai Pharmaceuticals | Others | | | YEN | 25,600 | 21,700 | 225 | 191 | -34 | -15% |
| 157 | Chugai Pharmaceuticals | Overseas | | | YEN | 74,300 | 82,200 | 654 | 723 | 69 | 11% |
| 158 | Chugai Pharmaceuticals | Domestic sales (excluding Tamiflu) | | | YEN | 349,500 | 378,000 | 3,076 | 3,326 | 250 | 8% |
| 159 | Chugai Pharmaceuticals | Tamiflu Sales | Oseltamivir Phosphate | Anti-Viral | YEN | 13,000 | 8,200 | 114 | 72 | -42 | -37% |
| 160 | Chugai Pharmaceuticals | Total Sales | | | YEN | 436,900 | 468,400 | 3,845 | 4,122 | 277 | 7% |
| 161 | Chugai Pharmaceuticals | Royalties and Other Operating Income | | | YEN | 24,200 | 30,400 | 213 | 268 | 55 | 26% |
| 162 | Chugai Pharmaceuticals | Total Revenues | | | YEN | 461,100 | 498,800 | 4,058 | 4,389 | 331 | 8% |
| 163 | Eli Lilly | Zyprexa | Olanzapine | Neuroscience and Mental Health | USD | 1,037 | 940 | 1,037 | 940 | -97 | -9% |
| 164 | Eli Lilly | Cymbalta | Duloxetine | Neuroscience and Mental Health | USD | 1,615 | 1,028 | 1,615 | 1,028 | -587 | -36% |
| 165 | Eli Lilly | Strattera | Atomoxetine | Neuroscience and Mental Health | USD | 739 | 784 | 739 | 784 | 45 | 6% |
| 166 | Eli Lilly | Prozac Family | Fluoxetine | Neuroscience and Mental Health | USD | 170 | 155 | 170 | 155 | -15 | -9% |
| 167 | Eli Lilly | Amyvid | Florbetapir | Neuroscience and Mental Health | USD | 3 | 6 | 3 | 6 | 3 | 100% |
| 168 | Eli Lilly | Other Neuroscience | | | USD | 32 | 23 | 32 | 23 | -9 | -28% |
| 169 | Eli Lilly | Total Neuroscience | | | USD | 3,596 | 2,935 | 3,596 | 2,935 | -661 | -18% |
| 170 | Eli Lilly | Humalog | Insulin lispro | Diabetes | USD | 2,785 | 2,842 | 2,785 | 2,842 | 57 | 2% |
| 171 | Eli Lilly | Humulin | Insulin Isophane | Diabetes | USD | 1,400 | 1,307 | 1,400 | 1,307 | -93 | -7% |
| 172 | Eli Lilly | Evista | Raloxifene | Bone Health | USD | 420 | 237 | 420 | 237 | -183 | -44% |
| 173 | Eli Lilly | Forteo | Teriparatide | Bone Health | USD | 1,322 | 1,348 | 1,322 | 1,348 | 26 | 2% |
| 174 | Eli Lilly | Humatrope | Somatropin | Harmonal Disorders | USD | 325 | 312 | 325 | 312 | -13 | -4% |
| 175 | Eli Lilly | Actos | Pioglitazone | Diabetes | USD | 42 | 28 | 42 | 28 | -14 | -33% |
| 176 | Eli Lilly | Axiron | Testosterone | Harmonal Disorders | USD | 171 | 155 | 171 | 155 | -16 | -9% |
| 177 | Eli Lilly | Glucagon | rDNA origin | Diabetes | USD | 105 | 121 | 105 | 121 | 16 | 15% |
| 178 | Eli Lilly | Trajenta | Linagliptin | Diabetes | USD | 329 | 357 | 329 | 357 | 28 | 9% |
| 179 | Eli Lilly | Jardiance | Empagliflozin | Diabetes | USD | 10 | 60 | 10 | 60 | 50 | 500% |
| 180 | Eli Lilly | Trulicity | Dulaglutide | Diabetes | USD | 10 | 249 | 10 | 249 | 239 | 2390% |
| 181 | Eli Lilly | Basaglar | Insulin glargine | Diabetes | USD | 0 | 11 | 0 | 11 | 11 | New Launch |
| 182 | Eli Lilly | Other Endocrinology* | | | USD | 21 | 9 | 21 | 9 | -12 | -57% |
| 183 | Eli Lilly | Total Endocrinology | | | USD | 6,939 | 7,037 | 6,939 | 7,037 | 98 | 1% |
| 184 | Eli Lilly | Alimta | Pemetrexed | Oncology | USD | 2,792 | 2,493 | 2,792 | 2,493 | -299 | -11% |
| 185 | Eli Lilly | Gemzar | Gemcitabine | Oncology | USD | 153 | 147 | 153 | 147 | -6 | -4% |
| 186 | Eli Lilly | Cyramza | Ramucirumab | Oncology | USD | 76 | 384 | 76 | 384 | 308 | 405% |
| 187 | Eli Lilly | Erbitux | Cetuximab | Oncology | USD | 373 | 485 | 373 | 485 | 112 | 30% |
| 188 | Eli Lilly | Other Oncology | | | USD | -1 | 1 | -1 | 1 | 2 | 200% |
| 189 | Eli Lilly | Total Oncology | | | USD | 3,393 | 3,510 | 3,393 | 3,510 | 117 | 3% |
| 190 | Eli Lilly | Cialis | Tadalafil | Sexual Health | USD | 2,291 | 2,311 | 2,291 | 2,311 | 20 | 1% |
| 191 | Eli Lilly | Reopro | Abciximab | Cardiovascular | USD | 111 | 98 | 111 | 98 | -13 | -12% |
| 192 | Eli Lilly | Effient | Prasugrel | Cardiovascular | USD | 522 | 523 | 522 | 523 | 1 | 0% |
| 193 | Eli Lilly | Adcirca | Tadalafil | Hypertension | USD | 73 | 76 | 73 | 76 | 3 | 4% |
| 194 | Eli Lilly | Other Cardiovascular* | | | USD | 57 | 61 | 57 | 61 | 4 | 7% |
| 195 | Eli Lilly | Total Cardiovascular | | | USD | 3,054 | 3,068 | 3,054 | 3,068 | 14 | 0% |
| 196 | Eli Lilly | Vancocin | Vancomycin hydrochloride | Anti-bacterial | USD | 99 | 90 | 99 | 90 | -9 | -9% |
| 197 | Eli Lilly | Other Pharma* | | | USD | 188 | 138 | 188 | 138 | -50 | -27% |
| 198 | Eli Lilly | Other Pharmaceutical | | | USD | 287 | 228 | 287 | 228 | -59 | -21% |
| 199 | Eli Lilly | Total Pharmaceuticals | | | USD | 17,269 | 16,778 | 17,269 | 16,778 | -491 | -3% |
| 200 | Eli Lilly | Food and Other | | | USD | 1,830 | 2,262 | 1,830 | 2,262 | 432 | 24% |
| 201 | Eli Lilly | Companion | | | USD | 517 | 919 | 517 | 919 | 402 | 78% |
| 202 | Eli Lilly | Total Animal Health | | | USD | 2,347 | 3,181 | 2,347 | 3,181 | 834 | 36% |
| 203 | Eli Lilly | Total Revenues | | | USD | 19,616 | 19,959 | 19,616 | 19,959 | 343 | 2% |
| 204 | Gilead Sciences | Sovaldi | Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 10,283 | 5,276 | 10,283 | 5,276 | -5,007 | -49% |
| 205 | Gilead Sciences | Atripla | Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 3,470 | 3,134 | 3,470 | 3,134 | -336 | -10% |
| 206 | Gilead Sciences | Truvada | Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 3,340 | 3,459 | 3,340 | 3,459 | 119 | 4% |
| 207 | Gilead Sciences | Harvoni | Ledipasvir and Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 2,127 | 13,864 | 2,127 | 13,864 | 11,737 | 552% |
| 208 | Gilead Sciences | Complera /Eviplera | Rilpivirine, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,228 | 1,427 | 1,228 | 1,427 | 199 | 16% |
| 209 | Gilead Sciences | Stribild | Cobicistat, Elvitegravir, Emtricitabine and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,197 | 1,825 | 1,197 | 1,825 | 628 | 52% |
| 210 | Gilead Sciences | Viread | Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,058 | 1,108 | 1,058 | 1,108 | 50 | 5% |
| 211 | Gilead Sciences | Genvoya | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide | Infectious Diseases (HIV, Hepatitis etc.) | USD | 0 | 45 | 0 | 45 | 45 | New Launch |
| 212 | Gilead Sciences | Other antiviral | | | USD | 88 | 69 | 88 | 69 | -19 | -22% |
| 213 | Gilead Sciences | Total antiviral products | | | USD | 22,791 | 30,207 | 22,791 | 30,207 | 7,416 | 33% |
| 214 | Gilead Sciences | Letairis | Ambrisentan | Antihypertensives | USD | 595 | 700 | 595 | 700 | 105 | 18% |
| 215 | Gilead Sciences | Ranexa | Ranolazine | Cardiovascular | USD | 510 | 588 | 510 | 588 | 78 | 15% |
| 216 | Gilead Sciences | AmBisome | Amphotericin B | Infectious Diseases (HIV, Hepatitis etc.) | USD | 388 | 350 | 388 | 350 | -38 | -10% |
| 217 | Gilead Sciences | Zydelig | Idelalisib | Oncology | USD | 23 | 132 | 23 | 132 | 109 | 474% |
| 218 | Gilead Sciences | others | | | USD | 167 | 174 | 167 | 174 | 7 | 4% |
| 219 | Gilead Sciences | Total Other Products | | | USD | 1,683 | 1,944 | 1,683 | 1,944 | 261 | 16% |
| 220 | Gilead Sciences | Total Product Sales | | | USD | 24,474 | 32,151 | 24,474 | 32,151 | 7,677 | 31% |
| 221 | Gilead Sciences | Royalty Contract and Other Revenues | | | USD | 416 | 488 | 416 | 488 | 72 | 17% |
| 222 | Gilead Sciences | Total Revenues | | | USD | 24,890 | 32,639 | 24,890 | 32,639 | 7,749 | 31% |
| 223 | GlaxoSmithKline | Anoro Ellipta | Umeclidinium and Vilanterol | Respiratory Disorders | GBP | 17 | 79 | 24 | 112 | 88 | 4% |
| 224 | GlaxoSmithKline | Avamys / Veramys | Fluticasone Furoate | Respiratory Disorders | GBP | 238 | 229 | 338 | 325 | -13 | -4% |
| 225 | GlaxoSmithKline | Flixotide /Flovent | Fluticasone Propionate | Respiratory Disorders | GBP | 702 | 623 | 997 | 885 | -112 | -11% |
| 226 | GlaxoSmithKline | Relvar /Breo Ellipta | Fluticasone Furoate | Respiratory Disorders | GBP | 67 | 257 | 95 | 365 | 270 | 284% |
| 227 | GlaxoSmithKline | Seretide /Advair | Salmeterol | Respiratory Disorders | GBP | 4,229 | 3,681 | 6,005 | 5,227 | -778 | -13% |
| 228 | GlaxoSmithKline | Ventolin | Albuterol | Respiratory Disorders | GBP | 665 | 620 | 944 | 880 | -64 | -7% |
| 229 | GlaxoSmithKline | Other | | | GBP | 280 | 252 | 398 | 358 | -40 | -10% |
| 230 | GlaxoSmithKline | Total Respiratory | | | GBP | 6,181 | 5,741 | 8,777 | 8,152 | -625 | -7% |
| 231 | GlaxoSmithKline | Total Oncology | | | GBP | 1,202 | 255 | 1,707 | 362 | -1,345 | -79% |
| 232 | GlaxoSmithKline | Avodart | Dutasteride | Urology | GBP | 805 | 657 | 1,143 | 933 | -210 | -18% |
| 233 | GlaxoSmithKline | Other | | | GBP | 160 | 201 | 227 | 285 | 58 | 26% |
| 234 | GlaxoSmithKline | Total Cardiovascular,metabolic and urology | | | GBP | 965 | 858 | 1,370 | 1,218 | -152 | -11% |
| 235 | GlaxoSmithKline | Benlysta | Belimumab | Rare Disease | GBP | 173 | 230 | 246 | 327 | 81 | 33% |
| 236 | GlaxoSmithKline | Other | | | GBP | 41 | 33 | 58 | 47 | -11 | -19% |
| 237 | GlaxoSmithKline | Total Immunoinflammation | | | GBP | 214 | 263 | 304 | 373 | 69 | 23% |
| 238 | GlaxoSmithKline | Dermatology | | | GBP | 481 | 412 | 683 | 585 | -98 | -14% |
| 239 | GlaxoSmithKline | Augmentin | Amoxicillin and Clavulanate Potassium | Anti-bacterial | GBP | 573 | 528 | 814 | 750 | -64 | -8% |
| 240 | GlaxoSmithKline | Other anti-bacterials | | | GBP | 215 | 184 | 305 | 261 | -44 | -14% |
| 241 | GlaxoSmithKline | Rare diseases | | | GBP | 417 | 371 | 592 | 527 | -65 | -11% |
| 242 | GlaxoSmithKline | Other | | | GBP | 721 | 704 | 1,024 | 1,000 | -24 | -2% |
| 243 | GlaxoSmithKline | Other pharmaceuticals | | | GBP | 2,407 | 2,199 | 3,418 | 3,123 | -295 | -9% |
| 244 | GlaxoSmithKline | Innovative Pharmaceuticals | | | GBP | 10,969 | 9,316 | 15,576 | 13,229 | -2,347 | -15% |
| 245 | GlaxoSmithKline | Coreg | Carvedilol | Antihypertensives | GBP | 124 | 123 | 176 | 175 | -1 | -1% |
| 246 | GlaxoSmithKline | Hepsera | Adefovir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 85 | 63 | 121 | 89 | -32 | -26% |
| 247 | GlaxoSmithKline | Imigran/Imitrex | Sumatriptan Succinate | Neuroscience and Mental Health | GBP | 172 | 160 | 244 | 227 | -17 | -7% |
| 248 | GlaxoSmithKline | Lamictal | Lamotrigine | Neuroscience and Mental Health | GBP | 531 | 531 | 754 | 754 | 0 | 0% |
| 249 | GlaxoSmithKline | Lovaza | Omega-3 Polyunsaturated Fatty Acids | Cardiovascular | GBP | 240 | 93 | 341 | 132 | -209 | -61% |
| 250 | GlaxoSmithKline | Requip | Ropinirole | Neuroscience and Mental Health | GBP | 109 | 93 | 155 | 132 | -23 | -15% |
| 251 | GlaxoSmithKline | Serevent | Salmeterol | Respiratory Disorders | GBP | 108 | 93 | 153 | 132 | -21 | -14% |
| 252 | GlaxoSmithKline | Seroxat/Paxil | Paroxetine Hydrochloride Hemihydrate | Neuroscience and Mental Health | GBP | 210 | 165 | 298 | 234 | -64 | -21% |
| 253 | GlaxoSmithKline | Valtrex | Valacyclovir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 154 | 165 | 219 | 234 | 15 | 7% |
| 254 | GlaxoSmithKline | Zeffix | Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 166 | 134 | 236 | 190 | -46 | -19% |
| 255 | GlaxoSmithKline | Other | | | GBP | 1,112 | 908 | 1,579 | 1,289 | -290 | -18% |
| 256 | GlaxoSmithKline | Established Products | | | GBP | 3,011 | 2,528 | 4,276 | 3,590 | -686 | -16% |
| 257 | GlaxoSmithKline | Global Pharmaceuticals | | | GBP | 13,980 | 11,844 | 19,852 | 16,818 | -3,034 | -15% |
| 258 | GlaxoSmithKline | Combivir | Lamivudine and zidovudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 59 | 34 | 84 | 48 | -36 | -43% |
| 259 | GlaxoSmithKline | Epzicom/Kivexa | Abacavir and Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 768 | 698 | 1,091 | 991 | -100 | -9% |
| 260 | GlaxoSmithKline | Lexiva/Agenerase | Fosamprenavir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 87 | 65 | 124 | 92 | -32 | -26% |
| 261 | GlaxoSmithKline | Selzentry | Maraviroc | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 136 | 124 | 193 | 176 | -17 | -9% |
| 262 | GlaxoSmithKline | Tivicay | Dolutegravir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 282 | 588 | 400 | 835 | 435 | 109% |
| 263 | GlaxoSmithKline | Triumeq | Abacavir, Dolutegravir and Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 0 | 730 | 0 | 1,037 | 1,037 | New Launch |
| 264 | GlaxoSmithKline | Trizivir | Abacavir, Lamivudine, and Zidovudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 36 | 26 | 51 | 37 | -14 | -27% |
| 265 | GlaxoSmithKline | Other | | | GBP | 130 | 57 | 185 | 81 | -104 | -56% |
| 266 | GlaxoSmithKline | ViiV Healthcare (HIV) | | | GBP | 1,498 | 2,322 | 2,127 | 3,297 | 1,170 | 55% |
| 267 | GlaxoSmithKline | Pharmaceuticals | | | GBP | 15,478 | 14,166 | 21,979 | 20,116 | -1,863 | -8% |
| 268 | GlaxoSmithKline | Bexsero | Meningococcal Group B Vaccine | Immunology | GBP | 0 | 115 | 0 | 163 | 163 | New Launch |
| 269 | GlaxoSmithKline | Boostrix | Vaccine | Vaccine | GBP | 317 | 358 | 450 | 508 | 58 | 13% |
| 270 | GlaxoSmithKline | Cervarix | Vaccine | Vaccine | GBP | 118 | 88 | 168 | 125 | -43 | -26% |
| 271 | GlaxoSmithKline | Fluarix, FluLaval | Vaccine | Vaccine | GBP | 215 | 268 | 305 | 381 | 76 | 25% |
| 272 | GlaxoSmithKline | Hepatitis | Vaccine | Vaccine | GBP | 558 | 540 | 792 | 767 | -25 | -3% |
| 273 | GlaxoSmithKline | Infanrix, Pediarix | Vaccine | Vaccine | GBP | 828 | 733 | 1,176 | 1,041 | -135 | -11% |
| 274 | GlaxoSmithKline | Menveo | Vaccine | Vaccine | GBP | 0 | 160 | 0 | 227 | 227 | New Launch |
| 275 | GlaxoSmithKline | Rabipur/Rabivert | Vaccine | Vaccine | GBP | 0 | 61 | 0 | 87 | 87 | New Launch |
| 276 | GlaxoSmithKline | Rotarix | Vaccine | Vaccine | GBP | 376 | 417 | 534 | 592 | 58 | 11% |
| 277 | GlaxoSmithKline | Synflorix | Vaccine | Vaccine | GBP | 398 | 381 | 565 | 541 | -24 | -4% |
| 278 | GlaxoSmithKline | Other | | | GBP | 382 | 536 | 542 | 761 | 219 | 40% |
| 279 | GlaxoSmithKline | Vaccines | | | GBP | 3,192 | 3,657 | 4,533 | 5,193 | 660 | 15% |
| 280 | GlaxoSmithKline | Total | | | GBP | 18,670 | 17,823 | 26,511 | 25,309 | -1,202 | -5% |
| 281 | GlaxoSmithKline | Consumer Healthcare Turnover | | | GBP | 4,336 | 6,028 | 6,157 | 8,560 | 2,403 | 39% |
| 282 | GlaxoSmithKline | Total Sales | | | GBP | 23,006 | 23,851 | 32,669 | 33,868 | 1,199 | 4% |
| 283 | Ipsen | Decapeptyl | Triptorelin | Hormonal Disorders | EURO | 317 | 334 | 349 | 367 | 18 | 5% |
| 284 | Ipsen | Somatuline | Lanreotide | Hormonal Disorders | EURO | 288 | 402 | 317 | 442 | 125 | 39% |
| 285 | Ipsen | Dysport | Abobotulinumtoxin A | Others | EURO | 255 | 280 | 281 | 308 | 27 | 10% |
| 286 | Ipsen | Nutropin | Somatropin Recombinant | Hormonal Disorders | EURO | 59 | 60 | 65 | 66 | 1 | 2% |
| 287 | Ipsen | Hexvix | Hexaminolevulinate HCl | Oncology | EURO | 16 | 17 | 18 | 19 | 1 | 6% |
| 288 | Ipsen | Increlex | Mecasermin | Hormonal Disorders | EURO | 13 | 20 | 14 | 22 | 8 | 57% |
| 289 | Ipsen | Total Specialty Care | | | EURO | 947 | 1,114 | 1,042 | 1,225 | 183 | 18% |
| 290 | Ipsen | Smecta | Diosmectite | Others | EURO | 121 | 115 | 133 | 127 | -6 | -5% |
| 291 | Ipsen | Tanakan | Ginkgo Biloba leaf extract | Cardiovascular | EURO | 63 | 52 | 69 | 57 | -12 | -17% |
| 292 | Ipsen | Forlax | Macrogol (aka polyethlene glycol) | Others | EURO | 39 | 40 | 43 | 44 | 1 | 2% |
| 293 | Ipsen | Total Primary Care | | | EURO | 328 | 330 | 361 | 363 | 2 | 1% |
| 294 | Ipsen | Net Sales | | | EURO | 1,275 | 1,444 | 1,402 | 1,588 | 186 | 13% |
| 295 | Ipsen | Other Revenues | | | EURO | 58 | 76 | 63 | 84 | 21 | 33% |
| 296 | Ipsen | Total Revenues | | | EURO | 1,332 | 1,520 | 1,466 | 1,672 | 206 | 14% |
| 297 | Johnson & Johnson | Remicade | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | USD | 6,868 | 6,561 | 6,868 | 6,561 | -307 | -4% |
| 298 | Johnson & Johnson | Simponi/Simponi Aria | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 1,187 | 1,328 | 1,187 | 1,328 | 141 | 12% |
| 299 | Johnson & Johnson | Stelara | Ustekinumab | Immunology | USD | 2,072 | 2,474 | 2,072 | 2,474 | 402 | 19% |
| 300 | Johnson & Johnson | Other Products | | | USD | 66 | 39 | 66 | 39 | -27 | -41% |
| 301 | Johnson & Johnson | Total: Immunology | | | USD | 10,193 | 10,402 | 10,193 | 10,402 | 209 | 2% |
| 302 | Johnson & Johnson | Edurant | Rilpivirine | Infectious Diseases (HIV, Hepatitis etc.) | USD | 365 | 410 | 365 | 410 | 45 | 12% |
| 303 | Johnson & Johnson | Incivo | Telaprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 226 | 0 | 226 | 0 | -226 | -100% |
| 304 | Johnson & Johnson | Olysio/Sovriad | Simeprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 2,302 | 621 | 2,302 | 621 | -1,681 | -73% |
| 305 | Johnson & Johnson | Prezista | Darunavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,831 | 1,810 | 1,831 | 1,810 | -21 | -1% |
| 306 | Johnson & Johnson | Other Products | | | USD | 1,101 | 815 | 1,101 | 815 | -286 | -26% |
| 307 | Johnson & Johnson | Total: Infectious Diseases | | | USD | 5,825 | 3,656 | 5,825 | 3,656 | -2,169 | -37% |
| 308 | Johnson & Johnson | Concerta/ Methylphenidate | Methylphenidate | Neuroscience and Mental Health | USD | 599 | 821 | 599 | 821 | 222 | 37% |
| 309 | Johnson & Johnson | Invega | Paliperidone | Neuroscience and Mental Health | USD | 640 | 573 | 640 | 573 | -67 | -10% |
| 310 | Johnson & Johnson | Invega Sustenna / Xeplion | Paliperidone Palmitate | Neuroscience and Mental Health | USD | 1,588 | 1,830 | 1,588 | 1,830 | 242 | 15% |
| 311 | Johnson & Johnson | Risperdal Consta | Risperidone | Neuroscience and Mental Health | USD | 1,190 | 970 | 1,190 | 970 | -220 | -18% |
| 312 | Johnson & Johnson | Other Products | | | USD | 2,470 | 2,065 | 2,470 | 2,065 | -405 | -16% |
| 313 | Johnson & Johnson | Total: Neuroscience | | | USD | 6,487 | 6,259 | 6,487 | 6,259 | -228 | -4% |
| 314 | Johnson & Johnson | Imbruvica | Ibrutinib | Oncology | USD | 200 | 689 | 200 | 689 | 489 | 245% |
| 315 | Johnson & Johnson | Velcade | Bortezomib | Oncology | USD | 1,618 | 1,333 | 1,618 | 1,333 | -285 | -18% |
| 316 | Johnson & Johnson | Zytiga | Abiraterone Acetate | Oncology | USD | 2,237 | 2,231 | 2,237 | 2,231 | -6 | 0% |
| 317 | Johnson & Johnson | Other Products | | | USD | 402 | 442 | 402 | 442 | 40 | 10% |
| 318 | Johnson & Johnson | Total: Oncology | | | USD | 4,457 | 4,695 | 4,457 | 4,695 | 238 | 5% |
| 319 | Johnson & Johnson | Procrit/Eprex | Epoetin Alfa | Blood Related Disorders | USD | 1,238 | 1,068 | 1,238 | 1,068 | -170 | -14% |
| 320 | Johnson & Johnson | Xarelto | Rivaroxaban | Anticoagulants | USD | 1,522 | 1,868 | 1,522 | 1,868 | 346 | 23% |
| 321 | Johnson & Johnson | Invokana / Invokamet | Canagliflozin | Type 2 diabetes | USD | 586 | 1,308 | 586 | 1,308 | 722 | 123% |
| 322 | Johnson & Johnson | Other Products | | | USD | 2,231 | 2,174 | 2,231 | 2,174 | -57 | -3% |
| 323 | Johnson & Johnson | Total: Other Prescription Products | | | USD | 5,577 | 6,418 | 5,577 | 6,418 | 841 | 15% |
| 324 | Johnson & Johnson | Contribution of Other Products | | | USD | 6,830 | 0 | 6,830 | 0 | -6,830 | -100% |
| 325 | Johnson & Johnson | Total Pharmaceuticals | | | USD | 32,313 | 31,430 | 32,313 | 31,430 | -883 | -3% |
| 326 | Johnson & Johnson | Consumer Health Care | | | USD | 14,496 | 13,507 | 14,496 | 13,507 | -989 | -7% |
| 327 | Johnson & Johnson | Medical Devices | | | USD | 27,522 | 25,137 | 27,522 | 25,137 | -2,385 | -9% |
| 328 | Johnson & Johnson | Total All Divisions | | | USD | 74,331 | 70,074 | 74,331 | 70,074 | -4,257 | -6% |
| 329 | Lundbeck | Abilify Maintena | Aripiprazole | Neuroscience and Mental Health | DKK | 209 | 669 | 31 | 100 | 69 | 223% |
| 330 | Lundbeck | Cipralex | Escitalopram Oxalate | Neuroscience and Mental Health | DKK | 4,647 | 2,591 | 697 | 389 | -308 | -44% |
| 331 | Lundbeck | Azilect | Rasagiline | Neuroscience and Mental Health | DKK | 1,497 | 1,457 | 225 | 219 | -6 | -3% |
| 332 | Lundbeck | Xenazine | Tetrabenazine | Rare Disease | DKK | 1,695 | 2,201 | 254 | 330 | 76 | 30% |
| 333 | Lundbeck | Sabril | Vigabatrin | Neuroscience and Mental Health | DKK | 716 | 985 | 107 | 148 | 41 | 38% |
| 334 | Lundbeck | Onfi | Clobazam | Neuroscience and Mental Health | DKK | 923 | 1,757 | 138 | 264 | 126 | 91% |
| 335 | Lundbeck | Rexulti | Brexpiprazole | Neuroscience and Mental Health | DKK | 0 | 117 | 0 | 18 | 18 | New Launch |
| 336 | Lundbeck | Brintellix | Vortioxetine | Neuroscience and Mental Health | DKK | 188 | 629 | 28 | 94 | 66 | 236% |
| 337 | Lundbeck | Northera | Droxidopa | Neurogenic Orthostatic Hypotension | DKK | 24 | 475 | 4 | 71 | 67 | 1675% |
| 338 | Lundbeck | Other Pharmaceuticals | | | DKK | 3,022 | 3,195 | 453 | 479 | 26 | 6% |
| 339 | Lundbeck | Other Revenues | | | DKK | 547 | 518 | 82 | 78 | -4 | -5% |
| 340 | Lundbeck | Total Sales | | | DKK | 13,468 | 14,594 | 2,020 | 2,189 | 169 | 8% |
| 341 | Merck & Co | Zetia | Ezetimibe | Cardiovascular | USD | 2,650 | 2,526 | 2,650 | 2,526 | -124 | -5% |
| 342 | Merck & Co | Vytorin | Ezetimibe and Simvastatin | Cardiovascular | USD | 1,516 | 1,251 | 1,516 | 1,251 | -265 | -17% |
| 343 | Merck & Co | Total Cardiovascular | | | USD | 4,166 | 3,777 | 4,166 | 3,777 | -389 | -9% |
| 344 | Merck & Co | Januvia | Sitagliptin | Diabetes | USD | 3,931 | 3,863 | 3,931 | 3,863 | -68 | -2% |
| 345 | Merck & Co | Janumet | Metformin and Sitagliptin | Diabetes | USD | 2,071 | 2,151 | 2,071 | 2,151 | 80 | 4% |
| 346 | Merck & Co | Total Diabetes | | | USD | 6,002 | 6,014 | 6,002 | 6,014 | 12 | 0% |
| 347 | Merck & Co | NuvaRing | Ethinyl Estradiol And Etonogestrel | Sexual Health | USD | 723 | 732 | 723 | 732 | 9 | 1% |
| 348 | Merck & Co | Implanin/Nexplanon | Etonogestrel | Sexual Health | USD | 502 | 588 | 502 | 588 | 86 | 17% |
| 349 | Merck & Co | Dulera | Formoterol and Mometasone | Respiratory Disorders | USD | 460 | 536 | 460 | 536 | 76 | 17% |
| 350 | Merck & Co | Follistim AQ | Follicle Stimulating Hormone | Sexual Health | USD | 412 | 383 | 412 | 383 | -29 | -7% |
| 351 | Merck & Co | General Medicine and Women's Health | | | USD | 2,097 | 2,239 | 2,097 | 2,239 | 142 | 7% |
| 352 | Merck & Co | PegIntron | Peginterferon alfa-2b | Infectious Diseases (HIV, Hepatitis etc.) | USD | 381 | 182 | 381 | 182 | -199 | -52% |
| 353 | Merck & Co | Total Hepatitis | | | USD | 381 | 182 | 381 | 182 | -199 | -52% |
| 354 | Merck & Co | Isentress | Raltegravir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,673 | 1,511 | 1,673 | 1,511 | -162 | -11% |
| 355 | Merck & Co | Total HIV | | | USD | 1,673 | 1,511 | 1,673 | 1,511 | -162 | -11% |
| 356 | Merck & Co | Cubicin | Daptomycin | Anti-bacterial | USD | 25 | 1,127 | 25 | 1,127 | 1,102 | 4408% |
| 357 | Merck & Co | Cancidas | Caspofungin | Anti-fungal | USD | 681 | 573 | 681 | 573 | -108 | -16% |
| 358 | Merck & Co | Invanz | Ertapenem | Anti-bacterial | USD | 529 | 569 | 529 | 569 | 40 | 8% |
| 359 | Merck & Co | Noxafil | Posaconazole | Anti-fungal | USD | 402 | 487 | 402 | 487 | 85 | 21% |
| 360 | Merck & Co | Bridion | Sugammadex | Neuroscience and Mental Health | USD | 340 | 353 | 340 | 353 | 13 | 4% |
| 361 | Merck & Co | Primaxin | Imipenem and Cilastatin | Anti-bacterial | USD | 329 | 313 | 329 | 313 | -16 | -5% |
| 362 | Merck & Co | Total Hospital Acute Care | | | USD | 2,305 | 3,421 | 2,305 | 3,421 | 1,116 | 48% |
| 363 | Merck & Co | Remicade | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | USD | 2,372 | 1,794 | 2,372 | 1,794 | -578 | -24% |
| 364 | Merck & Co | Simponi | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 689 | 690 | 689 | 690 | 1 | 0% |
| 365 | Merck & Co | Total Immunology | | | USD | 3,061 | 2,484 | 3,061 | 2,484 | -577 | -19% |
| 366 | Merck & Co | Keytruda | Pembrolizumab | Oncology | USD | 55 | 566 | 55 | 566 | 511 | 929% |
| 367 | Merck & Co | Emend | Aprepitant | Others | USD | 553 | 535 | 553 | 535 | -18 | -3% |
| 368 | Merck & Co | Temodar | Temozolomide | Oncology | USD | 350 | 312 | 350 | 312 | -38 | -12% |
| 369 | Merck & Co | Total Oncology | | | USD | 957 | 1,414 | 957 | 1,414 | 457 | 48% |
| 370 | Merck & Co | Nasonex | Mometasone Furoate | Respiratory Disorders | USD | 1,099 | 858 | 1,099 | 858 | -241 | -22% |
| 371 | Merck & Co | Singulair | Montelukast Sodium | Respiratory Disorders | USD | 1,092 | 931 | 1,092 | 931 | -161 | -15% |
| 372 | Merck & Co | Clarinex | Desloratadine | Immunology (Organ Transplant, Arthritis etc.) | USD | 232 | 187 | 232 | 187 | -45 | -19% |
| 373 | Merck & Co | Total Respiratory | | | USD | 2,423 | 1,976 | 2,423 | 1,976 | -447 | -18% |
| 374 | Merck & Co | Cozaar/Hyzaar | Losartan and Hydrochlorothiazide | Antihypertensives | USD | 806 | 667 | 806 | 667 | -139 | -17% |
| 375 | Merck & Co | Arcoxia | Etoricoxib | Immunology (Organ Transplant, Arthritis etc.) | USD | 519 | 471 | 519 | 471 | -48 | -9% |
| 376 | Merck & Co | Fosamax | Alendronate | Bone Health | USD | 470 | 359 | 470 | 359 | -111 | -24% |
| 377 | Merck & Co | Propecia | Finasteride | Others | USD | 264 | 183 | 264 | 183 | -81 | -31% |
| 378 | Merck & Co | Zocor | Simvastatin | Antihypertensives | USD | 258 | 217 | 258 | 217 | -41 | -16% |
| 379 | Merck & Co | Total Other | | | USD | 2,317 | 1,897 | 2,317 | 1,897 | -420 | -18% |
| 380 | Merck & Co | Gardasil/Gardasil 9 | Vaccine | Oncology | USD | 1,738 | 1,908 | 1,738 | 1,908 | 170 | 10% |
| 381 | Merck & Co | ProQuad/M-M-R II/ Varivax | Vaccine | Vaccine | USD | 1,394 | 1,505 | 1,394 | 1,505 | 111 | 8% |
| 382 | Merck & Co | Zostavax | Vaccine | Infectious Diseases (HIV, Hepatitis etc.) | USD | 765 | 749 | 765 | 749 | -16 | -2% |
| 383 | Merck & Co | Pneumovax 23 | Vaccine | Vaccine | USD | 746 | 542 | 746 | 542 | -204 | -27% |
| 384 | Merck & Co | RotaTeq | Vaccine | Vaccine | USD | 659 | 610 | 659 | 610 | -49 | -7% |
| 385 | Merck & Co | Total Vaccine | | | USD | 5,302 | 5,314 | 5,302 | 5,314 | 12 | 0% |
| 386 | Merck & Co | Other Pharmaceutical | | | USD | 5,356 | 4,553 | 5,356 | 4,553 | -803 | -15% |
| 387 | Merck & Co | Animal Health | | | USD | 3,454 | 3,324 | 3,454 | 3,324 | -130 | -4% |
| 388 | Merck & Co | Consumer Care | | | USD | 1,547 | 3 | 1,547 | 3 | -1,544 | -100% |
| 389 | Merck & Co | Other Revenues | | | USD | 1,194 | 1,389 | 1,194 | 1,389 | 195 | 16% |
| 390 | Merck & Co | Pharmaceuticals | | | USD | 36,042 | 34,782 | 36,042 | 34,782 | -1,260 | -3% |
| 391 | Merck & Co | Total Sales | | | USD | 42,237 | 39,498 | 42,237 | 39,498 | -2,739 | -6% |
| 392 | Novartis | Gleevec/Glivec | Imatinib | Oncology | USD | 4,746 | 4,658 | 4,746 | 4,658 | -88 | -2% |
| 393 | Novartis | Tasigna | Nilotinib | Oncology | USD | 1,529 | 1,632 | 1,529 | 1,632 | 103 | 7% |
| 394 | Novartis | Subtotal Bcr-Abl franchise | | | USD | 6,275 | 6,290 | 6,275 | 6,290 | 15 | 0% |
| 395 | Novartis | Sandostatin | Octreotide | Oncology | USD | 1,650 | 1,630 | 1,650 | 1,630 | -20 | -1% |
| 396 | Novartis | Afinitor/Votubia | Everolimus | Oncology | USD | 1,575 | 1,607 | 1,575 | 1,607 | 32 | 2% |
| 397 | Novartis | Exjade | Deferasirox | Oncology | USD | 926 | 917 | 926 | 917 | -9 | -1% |
| 398 | Novartis | Votrient | Pazopanib | Oncology | USD | 0 | 565 | 0 | 565 | 565 | New Launch |
| 399 | Novartis | Tafinlar/Mekinist | Dabrafenib/ Trametinib | Oncology | USD | 0 | 453 | 0 | 453 | 453 | New Launch |
| 400 | Novartis | Jakavi | Ruxolitinib | Oncology | USD | 279 | 410 | 279 | 410 | 131 | 47% |
| 401 | Novartis | Revolade/Promacta | Eltrombopag olamine/ eltrombopag | Oncology | USD | 0 | 402 | 0 | 402 | 402 | New Launch |
| 402 | Novartis | Femara | Letrozole | Oncology | USD | 380 | 304 | 380 | 304 | -76 | -20% |
| 403 | Novartis | Zykadia | Ceritinib | Oncology | USD | 31 | 79 | 31 | 79 | 48 | 155% |
| 404 | Novartis | Other | | | USD | 587 | 819 | 587 | 819 | 232 | 40% |
| 405 | Novartis | Total Oncology products | | | USD | 11,703 | 13,476 | 11,703 | 13,476 | 1,773 | 15% |
| 406 | Novartis | Gilenya | Fingolimod | Neuroscience and Mental Health | USD | 2,477 | 2,776 | 2,477 | 2,776 | 299 | 12% |
| 407 | Novartis | Exelon/Exelon Patch | Rivastigmine | Neuroscience and Mental Health | USD | 1,009 | 728 | 1,009 | 728 | -281 | -28% |
| 408 | Novartis | Comtan/Stalevo | Entacapone | Neuroscience and Mental Health | USD | 371 | 294 | 371 | 294 | -77 | -21% |
| 409 | Novartis | other | | | USD | 243 | 141 | 243 | 141 | -102 | -42% |
| 410 | Novartis | Total Neuroscience Products | | | USD | 4,100 | 3,939 | 4,100 | 3,939 | -161 | -4% |
| 411 | Novartis | Lucentis | Ranibizumab | Opthamology | USD | 2,441 | 2,060 | 2,441 | 2,060 | -381 | -16% |
| 412 | Novartis | Other | | | USD | 63 | 50 | 63 | 50 | -13 | -21% |
| 413 | Novartis | Total Retina | | | USD | 2,504 | 2,110 | 2,504 | 2,110 | -394 | -16% |
| 414 | Novartis | Neoral/Sandimmun | Cyclosporine | Immunology (Organ Transplant, Arthritis etc.) | USD | 684 | 570 | 684 | 570 | -114 | -17% |
| 415 | Novartis | Myfortic | Mycophenolic Acid | Immunology (Organ Transplant, Arthritis etc.) | USD | 543 | 441 | 543 | 441 | -102 | -19% |
| 416 | Novartis | Zortress/Certican | Everolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 327 | 335 | 327 | 335 | 8 | 2% |
| 417 | Novartis | Cosentyx | Secukinumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 0 | 261 | 0 | 261 | 261 | New Launch |
| 418 | Novartis | Ilaris | Canakinumab | Rare Disease | USD | 199 | 236 | 199 | 236 | 37 | 19% |
| 419 | Novartis | Other | | | USD | 173 | 160 | 173 | 160 | -13 | -8% |
| 420 | Novartis | Subtotal Immunology and Dermatology excluding Everolimus stent drug | | | USD | 1,926 | 2,003 | 1,926 | 2,003 | 77 | 4% |
| 421 | Novartis | Everolimus stent drug | Everolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 205 | 134 | 205 | 134 | -71 | -35% |
| 422 | Novartis | Total Immunology and Dermatology | | | USD | 2,131 | 2,137 | 2,131 | 2,137 | 6 | 0% |
| 423 | Novartis | Ultibro Breezhaler | Indacaterol / Glycopyrronium Bromide? | Respiratory Disorders | USD | 118 | 260 | 118 | 260 | 142 | 120% |
| 424 | Novartis | Onbrez Breezhaler/Arcapta Neohaler | Indacaterol Maleate | Respiratory Disorders | USD | 220 | 166 | 220 | 166 | -54 | -25% |
| 425 | Novartis | Seebri Breezhaler | Glycopyrronium Bromide | Respiratory Disorders | USD | 146 | 150 | 146 | 150 | 4 | 3% |
| 426 | Novartis | Subtotal COPD Portfolio | | | USD | 484 | 576 | 484 | 576 | 92 | 19% |
| 427 | Novartis | Xolair | Omalizumab | Respiratory Disorders | USD | 777 | 755 | 777 | 755 | -22 | -3% |
| 428 | Novartis | Other | | | USD | 320 | 263 | 320 | 263 | -57 | -18% |
| 429 | Novartis | Total Respiratory | | | USD | 1,581 | 1,594 | 1,581 | 1,594 | 13 | 1% |
| 430 | Novartis | Galvus | Vildagliptin | Diabetes | USD | 1,224 | 1,140 | 1,224 | 1,140 | -84 | -7% |
| 431 | Novartis | Entresto | Sacubitril/Valsartan | Cardiovascular | USD | 0 | 21 | 0 | 21 | 21 | New Launch |
| 432 | Novartis | Other | | | USD | 8 | 0 | 8 | 0 | -8 | -100% |
| 433 | Novartis | Total Cardio-Metabolic | | | USD | 1,232 | 1,161 | 1,232 | 1,161 | -71 | -6% |
| 434 | Novartis | Diovan | Hydrochlorothiazide and Valsartan | Antihypertensives | USD | 2,345 | 1,284 | 2,345 | 1,284 | -1,061 | -45% |
| 435 | Novartis | Exforge | Amlodipine and Valsartan. | Antihypertensives | USD | 1,396 | 1,047 | 1,396 | 1,047 | -349 | -25% |
| 436 | Novartis | Voltaren | Diclofenac | Others | USD | 632 | 558 | 632 | 558 | -74 | -12% |
| 437 | Novartis | Ritalin/Focalin | Methylphenidate | Neuroscience and Mental Health | USD | 492 | 365 | 492 | 365 | -127 | -26% |
| 438 | Novartis | Other | | | USD | 3,675 | 2,774 | 3,675 | 2,774 | -901 | -25% |
| 439 | Novartis | Total Established medicines | | | USD | 8,540 | 6,028 | 8,540 | 6,028 | -2,512 | -29% |
| 440 | Novartis | Total Division net Sales | | | USD | 31,791 | 30,445 | 31,791 | 30,445 | -1,346 | -4% |
| 441 | Novartis | Of which Growth products | | | USD | 11,289 | 13,532 | 11,289 | 13,532 | 2,243 | 20% |
| 442 | Novartis | Of which rest of portfolio | | | USD | 20,502 | 16,913 | 20,502 | 16,913 | -3,589 | -18% |
| 443 | Novartis | Net Sales by Alcon | | | USD | 10,827 | 9,812 | 10,827 | 9,812 | -1,015 | -9% |
| 444 | Novartis | Net Sales by Sandoz | | | USD | 9,562 | 9,157 | 9,562 | 9,157 | -405 | -4% |
| 445 | Novartis | Total Sales by Continuing operation | | | USD | 52,180 | 49,414 | 52,180 | 49,414 | -2,766 | -6% |
| 446 | Novartis | Total Sales by discontinuing operation | | | USD | 5,816 | 601 | 5,816 | 601 | -5,215 | -90% |
| 447 | Novartis | Total Group Net Sales | | | USD | 57,996 | 50,015 | 57,996 | 50,015 | -7,981 | -14% |
| 448 | Novo Nordisk | New-generation Insulin | Insulin | Diabetes | DKK | 658 | 1,438 | 99 | 216 | 117 | 118% |
| 449 | Novo Nordisk | NovoRapid/NovoLog | Insulin | Diabetes | DKK | 17,449 | 20,720 | 2,617 | 3,108 | 491 | 19% |
| 450 | Novo Nordisk | NovoMix/ NovoLog Mix | Insulin | Diabetes | DKK | 9,871 | 11,144 | 1,481 | 1,672 | 191 | 13% |
| 451 | Novo Nordisk | Levemir | Insulin | Diabetes | DKK | 14,217 | 18,300 | 2,133 | 2,745 | 612 | 29% |
| 452 | Novo Nordisk | Modern Insulins (Insulin analogues) | | Diabetes | DKK | 41,537 | 50,164 | 6,231 | 7,525 | 1,294 | 21% |
| 453 | Novo Nordisk | Human Insulins | Insulin | Diabetes | DKK | 10,298 | 11,231 | 1,545 | 1,685 | 140 | 9% |
| 454 | Novo Nordisk | Victoza | Liraglutide | Diabetes | DKK | 13,426 | 18,027 | 2,014 | 2,704 | 690 | 34% |
| 455 | Novo Nordisk | Other diabetes and obesity care | | | DKK | 1,728 | 4,730 | 609 | 710 | 101 | 17% |
| 456 | Novo Nordisk | Total Diabetes Care | | | DKK | 69,980 | 85,590 | 10,497 | 12,839 | 2,342 | 22% |
| 457 | Novo Nordisk | Haemophilia | Recombinant Human Coagulation Factor VIIa | Blood Related Disorders | DKK | 9,304 | 10,647 | 1,396 | 1,597 | 201 | 14% |
| 458 | Novo Nordisk | Norditropin | Somatropin | Hormonal Disorders | DKK | 6,506 | 7,820 | 976 | 1,173 | 197 | 20% |
| 459 | Novo Nordisk | Other Biopharmaceuticals | | | DKK | 3,016 | 3,870 | 452 | 581 | 129 | 29% |
| 460 | Novo Nordisk | Total Biopharmaceuticals | | | DKK | 18,826 | 22,337 | 2,824 | 3,351 | 527 | 19% |
| 461 | Novo Nordisk | Total Sales | | | DKK | 88,806 | 107,927 | 13,321 | 16,189 | 2,868 | 22% |
| 462 | Otsuka Holdings | Abilify | Aripiprazole | Neuroscience and Mental Health | YEN | 507,400 | 347,500 | 4,465 | 3,058 | -1,407 | -32% |
| 463 | Otsuka Holdings | Others | | | YEN | 376,000 | 624,300 | 899 | 1,278 | 379 | 42% |
| 464 | Otsuka Holdings | Total Pharmaceuticals | | | YEN | 883,500 | 971,800 | 7,775 | 8,552 | 777 | 10% |
| 465 | Otsuka Holdings | Total Nutraceuticals | | | YEN | 238,200 | 330,200 | 2,096 | 2,906 | 810 | 39% |
| 466 | Otsuka Holdings | Total Consumer Products | | | YEN | 34,500 | 43,200 | 304 | 380 | 76 | 25% |
| 467 | Otsuka Holdings | Others | | | YEN | 102,200 | 145,200 | 3,309 | 5,494 | 2,185 | 66% |
| 468 | Otsuka Holdings | Total | | | YEN | 1,258,400 | 1,490,400 | 11,074 | 13,116 | 2,042 | 18% |
| 469 | Otsuka Holdings | Corporate/Eliminations | | | YEN | -34,200 | -45,200 | -301 | -398 | -97 | 32% |
| 470 | Otsuka Holdings | Total Consolidated | | | YEN | 1,224,300 | 1,445,200 | 10,774 | 12,718 | 1,944 | 18% |
| 471 | Pfizer Inc. | Lyrica GIP | Pregabalin | Neuroscience and Mental Health | USD | 3,350 | 3,655 | 3,350 | 3,655 | 305 | 9% |
| 472 | Pfizer Inc. | Enbrel (Outside the U.S. and Canada) | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | 3,850 | 3,333 | 3,850 | 3,333 | -517 | -13% |
| 473 | Pfizer Inc. | Viagra GIP | Sildenafil Citrate | Sexual Health | USD | 1,181 | 1,297 | 1,181 | 1,297 | 116 | 10% |
| 474 | Pfizer Inc. | BeneFIX | Coagulation Factor IX | Rare Disease | USD | 856 | 752 | 856 | 752 | -104 | -12% |
| 475 | Pfizer Inc. | Chantix/Champix | Varenicline | Neuroscience and Mental Health | USD | 647 | 671 | 647 | 671 | 24 | 4% |
| 476 | Pfizer Inc. | Genotropin | Somatropin | Rare Disease | USD | 723 | 617 | 723 | 617 | -106 | -15% |
| 477 | Pfizer Inc. | Refacto AF/Xyntha | Antihemophilic Factor (Recombinant) | Rare Disease | USD | 631 | 533 | 631 | 533 | -98 | -16% |
| 478 | Pfizer Inc. | Xeljanz | Tofacitinib citrate | Immunology (Organ Transplant, Arthritis etc.) | USD | 308 | 523 | 308 | 523 | 215 | 70% |
| 479 | Pfizer Inc. | Toviaz | Fesoterodine fumarate | Urology | USD | 288 | 267 | 288 | 267 | -21 | -7% |
| 480 | Pfizer Inc. | BMP | Bone Morphogenetic Proteins | Bone Health | USD | 228 | 232 | 228 | 232 | 4 | 2% |
| 481 | Pfizer Inc. | Somavert | Pegvisomant | Hormonal Disorders | USD | 229 | 218 | 229 | 218 | -11 | -5% |
| 482 | Pfizer Inc. | Rapamune | Sirolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 339 | 197 | 339 | 197 | -142 | -42% |
| 483 | Pfizer Inc. | Alliance revenues GIP | | | USD | 762 | 1,254 | 762 | 1,254 | 492 | 65% |
| 484 | Pfizer Inc. | All other GIP | | | USD | 469 | 405 | 469 | 405 | -64 | -14% |
| 485 | Pfizer Inc. | VOC | | | USD | 10,143 | 12,803 | 10,143 | 12,803 | 2,660 | 26% |
| 486 | Pfizer Inc. | Prevnar family | Pneumococcal 7-Valent Conjugate | Anti-bacterial | USD | 4,464 | 6,245 | 4,464 | 6,245 | 1,781 | 40% |
| 487 | Pfizer Inc. | Sutent | Sunitinib Malate | Oncology | USD | 1,174 | 1,120 | 1,174 | 1,120 | -54 | -5% |
| 488 | Pfizer Inc. | Ibrance | Palbociclib | Oncology | USD | 0 | 723 | 0 | 723 | 723 | New Launch |
| 489 | Pfizer Inc. | Xalkori | Crizotinib | Oncology | USD | 438 | 488 | 438 | 488 | 50 | 11% |
| 490 | Pfizer Inc. | Inlyta | Axitinib | Oncology | USD | 410 | 430 | 410 | 430 | 20 | 5% |
| 491 | Pfizer Inc. | FSME-IMMUN/TicoVac | Tick-Borne Encephalitis Virus | Immunology | USD | 0 | 104 | 0 | 104 | 104 | New Launch |
| 492 | Pfizer Inc. | All other V/O | | | USD | 211 | 298 | 211 | 298 | 87 | 41% |
| 493 | Pfizer Inc. | Consumer Healthcare | | | USD | 3,446 | 3,395 | 3,446 | 3,395 | -51 | -1% |
| 494 | Pfizer Inc. | Established Products Business | | | USD | 25,149 | 21,587 | 25,149 | 21,587 | -3,562 | -14% |
| 495 | Pfizer Inc. | Legacy Established Products | | | USD | 13,016 | 11,745 | 13,016 | 11,745 | -1,271 | -10% |
| 496 | Pfizer Inc. | Lipitor | Atorvastatin Calcium | Cardiovascular | USD | 2,061 | 1,860 | 2,061 | 1,860 | -201 | -10% |
| 497 | Pfizer Inc. | Premarin family | Conjugated Estrogens | Sexual Health | USD | 1,076 | 1,018 | 1,076 | 1,018 | -58 | -5% |
| 498 | Pfizer Inc. | Norvasc | Amlodipine | Antihypertensives | USD | 1,112 | 991 | 1,112 | 991 | -121 | -11% |
| 499 | Pfizer Inc. | Xalatan/Xalacom | Latanoprost | Opthamology | USD | 495 | 399 | 495 | 399 | -96 | -19% |
| 500 | Pfizer Inc. | Zoloft | Sertraline | Neuroscience and Mental Health | USD | 423 | 374 | 423 | 374 | -49 | -12% |
| 501 | Pfizer Inc. | Relpax | Eletriptan Hydrobromide | Neuroscience and Mental Health | USD | 382 | 352 | 382 | 352 | -30 | -8% |
| 502 | Pfizer Inc. | EpiPen | Epinephrine | Immunology (Organ Transplant, Arthritis etc.) | USD | 294 | 339 | 294 | 339 | 45 | 15% |
| 503 | Pfizer Inc. | Effexor | Venlafaxine | Neuroscience and Mental Health | USD | 344 | 288 | 344 | 288 | -56 | -16% |
| 504 | Pfizer Inc. | Zithromax/Zmax | Azithromycin | Anti-bacterial | USD | 311 | 275 | 311 | 275 | -36 | -12% |
| 505 | Pfizer Inc. | Xanax/Xanax XR | Alprazolam | Neuroscience and Mental Health | USD | 253 | 224 | 253 | 224 | -29 | -11% |
| 506 | Pfizer Inc. | Cardura | Doxazosin mesylate | Antihypertensives | USD | 263 | 210 | 263 | 210 | -53 | -20% |
| 507 | Pfizer Inc. | Neurontin | Neurontin | Neuroscience and Mental Health | USD | 210 | 196 | 210 | 196 | -14 | -7% |
| 508 | Pfizer Inc. | Diflucan | Fluconazole | Anti-fungal | USD | 208 | 181 | 208 | 181 | -27 | -13% |
| 509 | Pfizer Inc. | Tikosyn | Dofetilide | Cardiovascular | USD | 141 | 179 | 141 | 179 | 38 | 27% |
| 510 | Pfizer Inc. | Depo-Provera | Medroxyprogesterone | Sexual Health | USD | 201 | 170 | 201 | 170 | -31 | -15% |
| 511 | Pfizer Inc. | Unasyn | Ampicillin-sulbactam | Anti-bacterial | USD | 96 | 118 | 96 | 118 | 22 | 23% |
| 512 | Pfizer Inc. | All other Legacy Established Products(f) | | | USD | 5,145 | 4,571 | 5,145 | 4,571 | -574 | -11% |
| 513 | Pfizer Inc. | Peri-LOE Products | | | USD | 8,855 | 5,326 | 8,855 | 5,326 | -3,529 | -40% |
| 514 | Pfizer Inc. | Lyrica GEP | Pregabalin | Neuroscience and Mental Health | USD | 1,818 | 1,183 | 1,818 | 1,183 | -635 | -35% |
| 515 | Pfizer Inc. | Zyvox | Linezolid | Anti-bacterial | USD | 1,352 | 883 | 1,352 | 883 | -469 | -35% |
| 516 | Pfizer Inc. | Celebrex | Celecoxib | Bone Health | USD | 2,699 | 830 | 2,699 | 830 | -1,869 | -69% |
| 517 | Pfizer Inc. | Pristiq | Desvenlafaxine | Neuroscience and Mental Health | USD | 737 | 715 | 737 | 715 | -22 | -3% |
| 518 | Pfizer Inc. | Vfend | Voriconazole | Anti-fungal | USD | 756 | 682 | 756 | 682 | -74 | -10% |
| 519 | Pfizer Inc. | Viagra GEP | Sildenafil Citrate | Sexual Health | USD | 504 | 411 | 504 | 411 | -93 | -18% |
| 520 | Pfizer Inc. | Revatio | Sildenafil | Antihypertensives | USD | 276 | 260 | 276 | 260 | -16 | -6% |
| 521 | Pfizer Inc. | All other Peri-LOE Products | | | USD | 714 | 362 | 714 | 362 | -352 | -49% |
| 522 | Pfizer Inc. | Sterile Injectable Pharmaceuticals(k) | | | USD | 3,277 | 3,944 | 3,277 | 3,944 | 667 | 20% |
| 523 | Pfizer Inc. | Medrol | Methylprednisolone | Immunology (Organ Transplant, Arthritis etc.) | USD | 381 | 402 | 381 | 402 | 21 | 6% |
| 524 | Pfizer Inc. | Sulperazon | Cefoperazone and Sulbactam | Urology | USD | 354 | 339 | 354 | 339 | -15 | -4% |
| 525 | Pfizer Inc. | Fragmin | Dalteparin | Anticoagulants | USD | 364 | 335 | 364 | 335 | -29 | -8% |
| 526 | Pfizer Inc. | Tygacil | Tigecycline | Anti-bacterial | USD | 323 | 304 | 323 | 304 | -19 | -6% |
| 527 | Pfizer Inc. | All other Sterile Injectable Pharmaceuticals(f) | | | USD | 1,855 | 2,563 | 1,855 | 2,563 | 708 | 38% |
| 528 | Pfizer Inc. | Infusion Systems | | | USD | 0 | 404 | 0 | 404 | 404 | New Launch |
| 529 | Pfizer Inc. | Biosimilars | | | USD | 0 | 63 | 0 | 63 | 63 | New Launch |
| 530 | Pfizer Inc. | Other Established Products | | | USD | 0 | 106 | 0 | 106 | 106 | - |
| 531 | Pfizer Inc. | Others | | | USD | 451 | 506 | 451 | 506 | 55 | 12% |
| 532 | Pfizer Inc. | Total Lyrica | Pregabalin | Neuroscience and Mental Health | USD | 5,168 | 4,839 | 5,168 | 4,839 | -329 | -6% |
| 533 | Pfizer Inc. | Total Viagra | Sildenafil Citrate | Sexual Health | USD | 1,685 | 1,708 | 1,685 | 1,708 | 23 | 1% |
| 534 | Pfizer Inc. | Total Alliance revenues | | | USD | 957 | 1,312 | 957 | 1,312 | 355 | 37% |
| 535 | Pfizer Inc. | GIP | | | USD | 13,861 | 13,955 | 13,861 | 13,955 | 94 | 1% |
| 536 | Pfizer Inc. | Innovative Products Business | | | USD | 24,005 | 26,758 | 24,005 | 26,758 | 2,753 | 11% |
| 537 | Pfizer Inc. | Total Revenues | | | USD | 49,605 | 48,851 | 49,605 | 48,851 | -754 | -2% |
| 538 | Roche | Avastin | Bevacizumab | Oncology | CHF | 6,417 | 6,684 | 6,481 | 6,751 | 270 | 4% |
| 539 | Roche | Herceptin | Trastuzumab | Oncology | CHF | 6,275 | 6,538 | 6,338 | 6,603 | 265 | 4% |
| 540 | Roche | MabThera/Rituxan | Rituximab | Oncology | CHF | 5,603 | 5,640 | 5,659 | 5,696 | 37 | 1% |
| 541 | Roche | Tarceva | Erlotinib | Oncology | CHF | 1,292 | 1,181 | 1,305 | 1,193 | -112 | -9% |
| 542 | Roche | Perjeta | Pertuzumab | Oncology | CHF | 918 | 1,445 | 927 | 1,459 | 532 | 57% |
| 543 | Roche | Xeloda | Capecitabine | Oncology | CHF | 776 | 513 | 784 | 518 | -266 | -34% |
| 544 | Roche | Kadcyla | Trastuzumab Emtansine | Oncology | CHF | 536 | 769 | 541 | 777 | 236 | 44% |
| 545 | Roche | Zelboraf | Vemurafenib | Oncology | CHF | 301 | 214 | 304 | 216 | -88 | -29% |
| 546 | Roche | Others | | | CHF | 679 | 677 | 686 | 684 | -2 | 0% |
| 547 | Roche | Total: Oncology | | | CHF | 22,797 | 23,661 | 23,025 | 23,898 | 873 | 4% |
| 548 | Roche | Actemra/RoActemra | Tocilizumab | Immunology (Organ Transplant, Arthritis etc.) | CHF | 1,224 | 1,432 | 1,236 | 1,446 | 210 | 17% |
| 549 | Roche | MabThera/Rituxan | Rituximab | Oncology | CHF | 1,297 | 1,405 | 1,310 | 1,419 | 109 | 8% |
| 550 | Roche | Xolair | Omalizumab | Respiratory Disorders | CHF | 975 | 1,277 | 985 | 1,290 | 305 | 31% |
| 551 | Roche | CellCept | Mycophenolate Mofetil | Immunology (Organ Transplant, Arthritis etc.) | CHF | 811 | 785 | 819 | 793 | -26 | -3% |
| 552 | Roche | Pulmozyme | Dornase Alfa | Rare Disease | CHF | 597 | 652 | 603 | 659 | 56 | 9% |
| 553 | Roche | Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | CHF | 44 | 563 | 45 | 569 | 524 | 1164% |
| 554 | Roche | Others | | | CHF | 139 | 114 | 185 | 115 | -70 | -38% |
| 555 | Roche | Total: Immunology | | | CHF | 5,087 | 6,228 | 5,138 | 6,290 | 1,152 | 22% |
| 556 | Roche | Pegasys | Peginterferon Alfa-2a | Infectious Diseases (HIV, Hepatitis etc.) | CHF | 1,015 | 538 | 1,025 | 543 | -482 | -47% |
| 557 | Roche | Tamiflu | Oseltamivir Phosphate | Infectious Diseases (HIV, Hepatitis etc.) | CHF | 959 | 705 | 969 | 712 | -257 | -27% |
| 558 | Roche | Valcyte/Cymevene | Ganciclovir and Valganciclovir | Immunology (Organ Transplant, Arthritis etc.) | CHF | 726 | 369 | 733 | 373 | -360 | -49% |
| 559 | Roche | Rocephin | Ceftriaxone | Neuroscience and Mental Health | CHF | 283 | 279 | 286 | 282 | -4 | -1% |
| 560 | Roche | Others | | | CHF | 211 | 160 | 213 | 162 | -51 | -24% |
| 561 | Roche | Total: Infectious Diseases | | | CHF | 3,194 | 2,051 | 3,226 | 2,072 | -1,154 | -36% |
| 562 | Roche | Lucentis | Ranibizumab | Opthamology | CHF | 1,701 | 1,520 | 1,718 | 1,535 | -183 | -11% |
| 563 | Roche | Total: Opthalmology | | | CHF | 1,701 | 1,520 | 1,718 | 1,535 | -183 | -11% |
| 564 | Roche | Madopar | Levodopa and Benserazide | Neuroscience and Mental Health | CHF | 292 | 275 | 295 | 278 | -17 | -6% |
| 565 | Roche | Others | | | CHF | 434 | 373 | 438 | 377 | -61 | -14% |
| 566 | Roche | Total: Neuroscience | | | CHF | 726 | 648 | 733 | 3,725 | 2,992 | 408% |
| 567 | Roche | Activase/TNKase | Tenecteplase | Cardiovascular | CHF | 747 | 935 | 754 | 944 | 190 | 25% |
| 568 | Roche | NeoRecormon/Epogin | Epoetin Beta and Epoetin Alfa | Blood Related Disorders | CHF | 460 | 366 | 465 | 370 | -95 | -20% |
| 569 | Roche | Mircera | Methoxy Polyethylene Glycol and Epoetin Beta | Blood Related Disorders | CHF | 417 | 475 | 421 | 480 | 59 | 14% |
| 570 | Roche | Nutropin | Somatropin | Hormonal Disorders | CHF | 214 | 207 | 216 | 209 | -7 | -3% |
| 571 | Roche | Others | | | CHF | 1,353 | 1,240 | 1,367 | 1,252 | -115 | -8% |
| 572 | Roche | Total Other therapeutic areas | | | CHF | 3,191 | 3,223 | 3,223 | 3,255 | 32 | 1% |
| 573 | Roche | Total Sales | | | CHF | 36,696 | 37,331 | 37,063 | 37,704 | 641 | 2% |
| 574 | Roche | Royalties and Other Operating Income | | | CHF | 2,273 | 2,119 | 2,296 | 2,140 | -156 | -7% |
| 575 | Roche | Total | | | CHF | 38,969 | 39,450 | 39,359 | 39,845 | 486 | 1% |
| 576 | Roche | Diagnostic Division | | | CHF | 10,766 | 10,814 | 10,874 | 10,922 | 48 | 0% |
| 577 | Roche | Royalties and Other Operating Income | | | CHF | 131 | 139 | 132 | 140 | 8 | 6% |
| 578 | Roche | Total Group Sale | | | CHF | 49,866 | 50,403 | 50,365 | 50,907 | 542 | 1% |
| 579 | Sanofi | Lantus | Insulin Glargine | Diabetes | EURO | 6,344 | 6,390 | 6,978 | 7,029 | 51 | 1% |
| 580 | Sanofi | Amaryl | Glimepiride | Diabetes | EURO | 360 | 393 | 396 | 432 | 36 | 9% |
| 581 | Sanofi | Apidra | Insulin Glulisine | Diabetes | EURO | 336 | 376 | 370 | 414 | 44 | 12% |
| 582 | Sanofi | Insuman | Insulin | Diabetes | EURO | 137 | 141 | 151 | 155 | 4 | 3% |
| 583 | Sanofi | Blood Glucose Meters | | Diabetes | EURO | 64 | 63 | 70 | 69 | -1 | -2% |
| 584 | Sanofi | Lyxumia | Lixisenatide | Diabetes | EURO | 27 | 38 | 30 | 42 | 12 | 40% |
| 585 | Sanofi | Afrezza | insulin human | Diabetes | EURO | 0 | 7 | 0 | 8 | 8 | New Launch |
| 586 | Sanofi | Toujeo | insulin glargine | Diabetes | EURO | 0 | 164 | 0 | 180 | 180 | New Launch |
| 587 | Sanofi | Other Products | | | EURO | 5 | 8 | 6 | 9 | 3 | 50% |
| 588 | Sanofi | Total: Diabetes | | | EURO | 7,273 | 7,580 | 8,000 | 8,338 | 338 | 4% |
| 589 | Sanofi | Jevtana | Cabazitaxel | Oncology | EURO | 273 | 321 | 300 | 353 | 53 | 18% |
| 590 | Sanofi | Taxotere | Docetaxel | Oncology | EURO | 266 | 222 | 293 | 244 | -49 | -17% |
| 591 | Sanofi | Thymoglobulin | Anti-thymocyte Globulin | Immunology (Organ Transplant, Arthritis etc.) | EURO | 217 | 256 | 239 | 282 | 43 | 18% |
| 592 | Sanofi | Eloxatin | Oxaliplatin | Oncology | EURO | 210 | 227 | 231 | 250 | 19 | 8% |
| 593 | Sanofi | Mozobil | Plerixafor | Oncology | EURO | 111 | 143 | 122 | 157 | 35 | 29% |
| 594 | Sanofi | Zaltrap | Aflibercept | Oncology | EURO | 69 | 77 | 76 | 85 | 9 | 12% |
| 595 | Sanofi | Other Products | | | EURO | 255 | 258 | 281 | 284 | 3 | 1% |
| 596 | Sanofi | Total: Oncology | | | EURO | 1,401 | 1,504 | 1,541 | 1,654 | 113 | 7% |
| 597 | Sanofi | Aubagio | Teriflunomide | Neuroscience and Mental Health | EURO | 433 | 871 | 476 | 958 | 482 | 101% |
| 598 | Sanofi | Lemtrada | Alemtuzumab | Neuroscience and Mental Health | EURO | 34 | 243 | 37 | 267 | 230 | 622% |
| 599 | Sanofi | Cerezyme | Imiglucerase | Rare Disease | EURO | 715 | 757 | 787 | 833 | 46 | 6% |
| 600 | Sanofi | Cerdelga | Eliglustat | Rare Disease | EURO | 4 | 66 | 4 | 73 | 69 | 1725% |
| 601 | Sanofi | Myozyme/Lumizyme | Alglucosidase alfa | Rare Disease | EURO | 542 | 650 | 596 | 715 | 119 | 20% |
| 602 | Sanofi | Fabrazyme | Agalsidase beta | Rare Disease | EURO | 460 | 592 | 506 | 651 | 145 | 29% |
| 603 | Sanofi | Aldurazyme | Laronidase | Rare Disease | EURO | 172 | 195 | 189 | 215 | 26 | 14% |
| 604 | Sanofi | Other Products | | | EURO | 244 | 290 | 268 | 319 | 51 | 19% |
| 605 | Sanofi | Total: Genzyme | | | EURO | 2,604 | 3,664 | 2,864 | 4,030 | 1,166 | 41% |
| 606 | Sanofi | Plavix | Clopidogrel Bisulfate | Cardiovascular | EURO | 1,862 | 1,929 | 2,048 | 2,122 | 74 | 4% |
| 607 | Sanofi | Lovenox | Enoxaparin Sodium | Anticoagulants | EURO | 1,699 | 1,719 | 1,869 | 1,891 | 22 | 1% |
| 608 | Sanofi | Aprovel/CoAprovel | Irbesartan / Irbesartan+Hydrochlorothiazide | Antihypertensives | EURO | 727 | 762 | 800 | 838 | 38 | 5% |
| 609 | Sanofi | Depakine | Valproate sodium | Neuroscience and Mental Health | EURO | 395 | 422 | 435 | 464 | 29 | 7% |
| 610 | Sanofi | Synvisc/Synvisc-One | Hylan G-F 20 | Bone Health | EURO | 352 | 413 | 387 | 454 | 67 | 17% |
| 611 | Sanofi | Renagel/Renvela | Sevelamer Hydrochloride and Sevelamer Carbonate | Urology | EURO | 684 | 935 | 752 | 1,029 | 277 | 37% |
| 612 | Sanofi | Multaq | Dronedarone | Cardiovascular | EURO | 290 | 341 | 319 | 375 | 56 | 18% |
| 613 | Sanofi | Stilnox/Ambien/Myslee | Zolpidem | Sleep Disorders | EURO | 306 | 306 | 337 | 337 | 0 | 0% |
| 614 | Sanofi | Tritace | Ramipril | Antihypertensives | EURO | 281 | 274 | 309 | 301 | -8 | -3% |
| 615 | Sanofi | Allegra | Fexofenadine Hydrochoride | Respiratory Disorders | EURO | 192 | 194 | 211 | 213 | 2 | 1% |
| 616 | Sanofi | Lasix | Furosemide | Cardiovascular | EURO | 164 | 162 | 180 | 178 | -2 | -1% |
| 617 | Sanofi | Targocid | Teicoplanin | Anti-bacterial | EURO | 162 | 160 | 178 | 176 | -2 | -1% |
| 618 | Sanofi | Orudis | Ketoprofen | Bone Health | EURO | 160 | 156 | 176 | 172 | -4 | -2% |
| 619 | Sanofi | Cordarone | Amiodarone Hydrochloride | Cardiovascular | EURO | 129 | 130 | 142 | 143 | 1 | 1% |
| 620 | Sanofi | Xatral | Alfuzosin | Urology | EURO | 94 | 95 | 103 | 105 | 2 | 2% |
| 621 | Sanofi | Actonel | Risedronate sodium | Bone Health | EURO | 82 | 23 | 90 | 25 | -65 | -72% |
| 622 | Sanofi | Auvi-Q/Allerject | Epinephrine | Cardiovascular | EURO | 72 | -5 | 79 | -6 | -85 | -108% |
| 623 | Sanofi | Other Products | | | EURO | 3,649 | 3,617 | 4,014 | 3,979 | -35 | -1% |
| 624 | Sanofi | Total: Other Prescription Products | | | EURO | 11,300 | 11,633 | 12,430 | 12,796 | 366 | 3% |
| 625 | Sanofi | Praluent | Alirocumab | Hypercholesterolaemia | EURO | 0 | 9 | 0 | 10 | 10 | New Launch |
| 626 | Sanofi | Consumer Health Care | | | EURO | 3,337 | 3,492 | 3,671 | 3,841 | 170 | 5% |
| 627 | Sanofi | Generics | | | EURO | 1,805 | 1,917 | 1,986 | 2,109 | 123 | 6% |
| 628 | Sanofi | Total Pharmaceuticals | | | EURO | 27,720 | 29,799 | 30,492 | 32,779 | 2,287 | 8% |
| 629 | Sanofi | Polio / Pertussis / Hib | Vaccine | | EURO | 1,154 | 1,348 | 1,269 | 1,483 | 214 | 17% |
| 630 | Sanofi | Adult Booster Vaccines | Vaccine | | EURO | 398 | 496 | 438 | 546 | 108 | 25% |
| 631 | Sanofi | Meningitis/Pneumonia | Vaccine | | EURO | 455 | 614 | 501 | 675 | 174 | 35% |
| 632 | Sanofi | Influenza Vaccines | Vaccine | | EURO | 1,178 | 1,322 | 1,296 | 1,454 | 158 | 12% |
| 633 | Sanofi | Travel And Other Endemics Vaccines | Vaccine | | EURO | 377 | 375 | 415 | 413 | -2 | 0% |
| 634 | Sanofi | Other Vaccines | | | EURO | 412 | 588 | 453 | 647 | 194 | 43% |
| 635 | Sanofi | Vaccine | Vaccine | | EURO | 3,974 | 4,743 | 4,371 | 5,217 | 846 | 19% |
| 636 | Sanofi | Total Group | | | EURO | 31,694 | 34,542 | 34,863 | 37,996 | 3,133 | 9% |
| 637 | Sanofi | Fipronil products | | Anti-parasiticide | EURO | 597 | 627 | 657 | 690 | 33 | 5% |
| 638 | Sanofi | Vaccines | Vaccine | | EURO | 720 | 804 | 792 | 884 | 92 | 12% |
| 639 | Sanofi | Avermectin products | | | EURO | 398 | 498 | 438 | 548 | 110 | 25% |
| 640 | Sanofi | Others | | | EURO | 248 | 586 | 273 | 645 | 372 | 136% |
| 641 | Sanofi | Animal Health | | | EURO | 2,076 | 2,515 | 2,284 | 2,767 | 483 | 21% |
| 642 | Sanofi | Total Sales | | | EURO | 33,770 | 37,057 | 37,147 | 40,763 | 3,616 | 10% |
| 643 | Teva | Copaxone | Glatiramer | Neuroscience and Mental Health | USD | 4,237 | 4,023 | 4,237 | 4,023 | -214 | -5% |
| 644 | Teva | Azilect | Rasagiline | Neuroscience and Mental Health | USD | 428 | 384 | 428 | 384 | -44 | -10% |
| 645 | Teva | Nuvigil | Armodafinil | Sleep Disorders | USD | 388 | 373 | 388 | 373 | -15 | -4% |
| 646 | Teva | Others | | | USD | 522 | 433 | 522 | 433 | -89 | -17% |
| 647 | Teva | Total Neuroscience | | | USD | 5,575 | 5,213 | 5,575 | 5,213 | -362 | -6% |
| 648 | Teva | Treanda | Bendamustine | Oncology | USD | 767 | 741 | 767 | 741 | -26 | -3% |
| 649 | Teva | Others | | | USD | 413 | 460 | 413 | 460 | 47 | 11% |
| 650 | Teva | Total Oncology | | | USD | 1,180 | 1,201 | 1,180 | 1,201 | 21 | 2% |
| 651 | Teva | ProAir | Albuterol Sulfate | Respiratory Disorders | USD | 478 | 549 | 478 | 549 | 71 | 15% |
| 652 | Teva | Qvar | Beclomethasone | Respiratory Disorders | USD | 286 | 392 | 286 | 392 | 106 | 37% |
| 653 | Teva | Others | | | USD | 193 | 188 | 193 | 188 | -5 | -3% |
| 654 | Teva | Total Respiratory | | | USD | 957 | 1,129 | 957 | 1,129 | 172 | 18% |
| 655 | Teva | Women's Health | | | USD | 504 | 461 | 504 | 461 | -43 | -9% |
| 656 | Teva | Other Specialilty Medicines | | | USD | 344 | 334 | 344 | 334 | -10 | -3% |
| 657 | Teva | Speciality Medicines | | | USD | 8,560 | 8,338 | 8,560 | 8,338 | -222 | -3% |
| 658 | Teva | All Others | | | USD | 1,898 | 1,768 | 1,898 | 1,768 | -130 | -7% |
| 659 | Teva | Generic Medicines | | | USD | 9,814 | 9,546 | 9,814 | 9,546 | -268 | -3% |
| 660 | Teva | Total Sales | | | USD | 20,272 | 19,652 | 20,272 | 19,652 | -620 | -3% |
| 661 | Vertex | Kalydeco | Ivacaftor | Respiratory Disorders | USD | 464 | 632 | 464 | 632 | 168 | 36% |
| 662 | Vertex | Orkambi | Lumacaftor/ Ivacaftor | Respiratory Disorders | USD | 0 | 351 | 0 | 351 | 351 | New Launch |
| 663 | Vertex | Incivek | Telaprevir | Gastrointestinal Disorders | USD | 24 | 18 | 24 | 18 | -6 | -25% |
| 664 | Vertex | Total Product Revenues | | | USD | 488 | 1,000 | 488 | 1,000 | 512 | 105% |
